2017 BANFF-SCT
Joint Scientific Meeting
BARCELONA
27-31 March 2017

Final programme
The Organising Committee would like to sincerely thank to the pharmaceutical industry for the economic support and special efforts that they have dedicated to this Meeting.

PLATINUM SPONSORS

Chiesi  
NOVARTIS  
Shire  
ONE LAMBDA

GOLD SPONSORS

Astellas

STANDARD SPONSORS

Pfizer  
SANOFI  
TEVA

OTHER COLLABORATORS

Alexion  
Biotest  
Diagnóstica Longwood
Endorsing societies 4
Committees 5
Welcome to Barcelona 6
General Information 7
Information for authors and speakers 10

**SCIENTIFIC PROGRAMME**

Overview of sessions 13
Monday 27 March 14
Tuesday 28 March 15
Wednesday 29 March 18
Thursday 30 March 24
Friday 31 March 29
Posters 32
Industry sponsored symposia 48
Index of speakers 50

Map of area 56
The Organising Committee of the 2017 Banff-SCT Joint Scientific Meeting would like to thank sincerely the following societies for the support they have given to this meeting.

**SPECIAL RECOGNITION TO**

Organització Catalana de Trasplantaments (OCATT)

**ENDORsing Societies**

Sociedad Española de Trasplante (SET)
Organización Nacional de Trasplantes (ONT)
Organització Catalana de Trasplantaments (OCATT)
European Society for Organ Transplantation (ESOT)
The Transplantation Society (TTS)
HONORARY PRESIDENCY
Hble. Mr. Antoni Comín i Oliveres
MINISTER OF HEALTH OF THE GENERALITAT DE CATALUNYA

ORGANISING COMMITTEE

BANFF BOARD
CHAIR
Kim Solez
TREASURER
Kim Solez
COUNCILLORS
Anthony J. Demetris
Denis Glotz
Alexandre Loupy
Michael Mihatsch
Brian Nankivell
Lorraine Racusen
Daniel Serón

SCT BOARD
PRESIDENT
Antonio Román
VICE PRESIDENT
Francesc J. Moreso
SECRETARY
Núria Masnou
COUNCILLORS
Gonzalo Crespo
Josep Maria Cruzado
Laura Lladó
Sonia Mirabet
Eduard Palou

SCIENTIFIC COMMITTEE

EXECUTIVE COMMITTEE
Mark Haas
Alexandre Loupy

COUNCILLORS
Carlos Bravo
Patrick Bruneval
Lluís Castells
Linda Cendales
Gonzalo Crespo
Josep Maria Cruzado
Anthony J. Demetris
Cinthia Drachenberg
Constantino Fondevila

Josep Maria Grinyó
Lluis Guirado
David Hwang
Núria Masnou
Jaume Martorell
Michael Mengel
Michael Mihatsch
Sonia Mirabet
Francesc Moreso
Frederic Oppenheimer
Eduard Palou
Julio Pascual
Elizabeth Pavlisko
Lorrain Racuse
Eulàlia Roig
Kim Solez

SCIENTIFIC AND TECHNICAL SECRETARIAT
To request any information regarding the scientific and social programmes, registration, accommodation or exhibitions, contact:

BANFF-SCT 2017 Meeting - AOPC
Edif Colon, Av. Drassanes 6
E-08001 Barcelona
Tel 933 027 541
congress@aopc.es
Dear colleagues, dear friends,
We would like to welcome you to the 2017 Banff-Catalan Transplantation Society joint scientific meeting in Barcelona. This meeting represents a great opportunity to share and learn about many relevant aspects of organ transplantation including antibody mediated rejection, telepathology and big data in transplant pathology, biomarkers and tolerance, key issues in clinical trials, regeneration vs repair, new technologies in allograft pathology, tissue engineering pathology, omics in transplantation, immunosuppression and personalized medicine, donation and major clinical advances in transplantation among others. Organ transplantation today represents first line therapy for organ failure and this meeting will help us to refine our knowledge of basic and clinical science to ensure a better future for our patients. The issues that will be discussed in this meeting represent the transplant medicine of tomorrow.

This joint meeting also represents a big opportunity for both societies to share experiences and knowledge in the field of transplantation. The Banff Foundation held a joint meeting with the Canadian Transplantation Society two years ago with excellent interaction between the two societies. After this first successful collaboration experience, the Banff Foundation contacted the Catalan Transplantation Society and the two societies decided to hold this joint meeting. This project was understood to be a good opportunity for both societies. On the one hand, Banff meetings have become renowned worldwide in organ transplantation pathology and other related basic aspects of transplant science over the past twenty-six years. On the other hand, Catalonia is one of the more active places regarding organ transplantation with remarkable contribution to the general knowledge in the field of transplantation. Also, the Catalan Transplantation Society has a long tradition in continuous medical education in the field of transplantation with periodic meetings and sessions. We are convinced that this mix will be productive for all of you and for both Societies.

We would like to thank the University of Barcelona for allowing us to use this building for our meeting. It is one of the less well known treasures of Barcelona.

Also, we would like to sincerely thank the pharmaceutical industry for their economic support and special efforts that they have dedicated to this meeting.

Finally, we invite you to enjoy the city, the university building and the social events that we have organized. We are convinced that the location of the meeting downtown will bring you the opportunity to enjoy this city. We feel sure that you will discover a new face of the city. It is early spring with very mild temperatures and good weather. This is an excellent opportunity to enjoy a walk downtown or other simple pleasurable activities. Welcome and enjoy!

Kim Soley
President of the BANFF Foundation

Antonio Román
President of the SCT and FCT
VENUE
Universitat de Barcelona
Campus Plaça Universitat
Gran Via de les Corts Catalanes 585
08007 Barcelona

REGISTRATION AND GENERAL INFORMATION
The secretariat and registration desk will be located on the first floor of the Universitat de Barcelona.

SECRETARIAT OPENING HOURS:
Monday 27 March     7.30 - 19.00
Tuesday 28 March     8.30 - 19.00
Wednesday 29 March   8.00 - 19.00
Thursday 30 March    7.30 - 19.00
Friday 31 March      8.30 - 14.00

REGISTRATION FEES

(A) FULL MEETING REGISTRATION

<table>
<thead>
<tr>
<th></th>
<th>Early by 31 January</th>
<th>Standard by 20 March</th>
<th>Onsite from 21 March</th>
</tr>
</thead>
<tbody>
<tr>
<td>Senior Attendants</td>
<td>600 €</td>
<td>700 €</td>
<td>800 €</td>
</tr>
<tr>
<td>Junior Attendants*</td>
<td>300 €</td>
<td>400 €</td>
<td>500 €</td>
</tr>
</tbody>
</table>

(B) REGISTRATION FOR LAST 3 DAYS

<table>
<thead>
<tr>
<th></th>
<th>Early by 31 January</th>
<th>Standard by 20 March</th>
<th>Onsite from 21 March</th>
</tr>
</thead>
<tbody>
<tr>
<td>Senior Attendants</td>
<td>400 €</td>
<td>500 €</td>
<td>600 €</td>
</tr>
<tr>
<td>Junior Attendants *</td>
<td>200 €</td>
<td>300 €</td>
<td>400 €</td>
</tr>
</tbody>
</table>

(C) INDUSTRY

<table>
<thead>
<tr>
<th></th>
<th>Early by 31 January</th>
<th>Standard by 20 March</th>
<th>Onsite from 21 March</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>600 €</td>
<td>700 €</td>
<td>800 €</td>
</tr>
</tbody>
</table>

Important: to benefit from the Junior Attendants’ registration fees, proof of status is mandatory:

Junior Attendants must be under 35 years of age at the time of the Meeting and/or still in training. Proof of age and/or training status is mandatory. A letter of confirmation from your Head of Unit may be uploaded during the registration process confirming that you are a resident or trainee.

Should your registration remain unpaid as of the deadline date for the fee you applied, registration fees will automatically be modified to late fees.
Registration fees include:

(A) Full Meeting Registration  Monday 27 to Friday 31 March 2017
- Admission to all scientific sessions
- Access to Exhibition area
- Coffee breaks during the meeting period
- Lunch box from 27 to 30 March
- Programme & Book of Abstracts through the website during the meeting

(B) Registration for the last 3 days  Wednesday 29 to Friday 31 March 2017
- Admission to all scientific sessions (29, 30 & 31 March, only)
- Access to Exhibition area
- Coffee breaks during the meeting period
- Lunch box from 27 to 30 March
- Programme & Book of Abstracts through the website during the meeting

(C) Full Meeting Registration (Industry)
- Admission to all scientific sessions
- Access to Exhibition area
- Coffee breaks during the meeting period
- Lunch box from 27 to 30 March
- Programme & Book of Abstracts through the website during the meeting

Please visit www.sctransplant.org/sct2017 for more information

BADGES
Your personal badge is your entrance ticket to the congress venue and all scientific sessions.

All participants and exhibitors are requested to wear their BANFF-SCT 2017 name badges at all times, in order to be given access to the Meeting venue. Participants not wearing the BANFF-SCT2017 badge will not be granted access past the registration area.

25.00€ (21% VAT included) will be charged for replacing a lost badge and for re-printing due to incorrect submission of names and/or company names or addresses.

Exhibitors are admitted into the exhibition area as well as the catering areas, but have no access to the lecture halls.
INDUSTRY EXHIBITION
The exhibition will be located on the ground floor in the main entrance hall of the Universitat de Barcelona.

Open every day at the following times:
Monday 27 March          9.30 to 18.30
Tuesday 28 March         9.30 to 18.30
Wednesday 29 March    9.30 to 18.30
Thursday 30 March       9.30 to 18.30
Friday 31 March              9.30 to 14.00

LIABILITY
By registering for the Meeting and/or by participating in the exhibition held along with the BANFF-SCT Joint Scientific Meeting, participants and exhibitors agree that the Organizing Committee or the Meeting Secretariat cannot accept liability for personal injuries sustained, or for loss or damage of property belonging to meeting participants, either during, or as a result of the meeting.

Please check the validity of your own personal insurance before travelling.

COFFEE AND LUNCHES
Coffee for breaks and lunch box for delegates are included in the registration fee and will be served in the Exhibition hall.

SPECIAL REQUIREMENTS
Please advise the Meeting Secretariat of any special physical requirements. Also inform us of any individual dietary needs (including vegetarian).

OFFICIAL CONGRESS APP
Official app for 2017 BANFF-SCT Joint Scientific Meeting is now available online at Google Play and Apple App Store.
INSTRUCTIONS FOR SPEAKERS AND AUTHORS

ORAL PRESENTATION GUIDELINES
All presentations should be based on PowerPoint 2003 or 2007 versions. Audiovisual components should be based on Quick-Time or Windows-Media-File formats.

Speakers and authors need to bring a copy of the presentation on a Flash drive (USB drive, memory stick). Please upload your presentation BEFORE the start of your session. Uploading may be done during coffee/lunch breaks. If you are speaking in the first session of the day, please arrive at 7.30 to upload your presentation or upload the day before if possible.

Orals will be presented in the Paraninff (Plenary) and Aula Magna (Parallel). You will not be using your own computer for the presentation. If your presentation needs to insert additional files (e.g. a video file embedded in your PowerPoint presentation), please make sure with the technician that these files work properly and are available for transfer as well. Please gauge the length of your presentation according to your allocated time. The chairperson will inform you when you are within a few minutes of the end of your allocated time, and will be instructed to cut-off speakers who run over time.

POSTER PRESENTATION GUIDELINES
There will be two posters sessions and authors are kindly requested to stay close to their posters for discussion with other participants as per the following schedule:

- Posters for Joint Poster Viewing Session 1 (final references from P1 to P38).
  - Poster set-up: from Tuesday 28 March from 8.00 to 13.00.
  - Poster dismantling: removed on Wednesday 29 March not later than 20.00, immediately after the end of the poster session.
- Posters for Joint Poster Viewing Session 2 (final references from P39 to P78).
  - Poster set-up: on Thursday 30 March from 8.00 to 13.00.
  - Poster dismantling: removed on Friday 31 March not later than 11.00.

Authors are kindly requested to stand by their posters at the following times:
Poster Viewing Session 1: Wednesday 29 March from 18.30 to 19.30
Poster Viewing Session 2: Thursday 30 March from 19.00 to 20.00

INFORMATION FOR THE PREPARATION OF POSTERS
Posters should be prepared in advance and should be brought in person by the author. Do not mail your poster. The poster must be placed in the panel number corresponding to the final number indicated in the acceptance letter.

The dimensions of the poster must not exceed 80cm wide by 120cm high (vertical orientation). Posters should be legible at a distance of 1.5 metres (60 inches) when reproduced on an A4 sheet of paper. The title, names of the authors, institutions, city and country should be indicated on the poster. It is advisable to organise your poster in sections: Introduction, Results and Conclusions.
Display material will be provided at the registration desk. Posters must be removed as per the above schedule - posters left on the panels will not be mailed to the authors after the congress. The 2017 BANFF-SCT Joint Scientific Meeting will not be responsible for loss or damage occurred to posters left on the panels.

**TRANSLANTATION PROCEEDINGS**
Transplantation Proceedings invites authors with accepted Abstracts for both oral and poster presentations the opportunity to submit a full manuscript to Transplantation Proceedings in conjunction with the 2017 BANFF-SCT Joint Scientific Meeting. Please see complete guidelines at www.sctranpsplant.org/sct2017

**COMPLIMENTARY PAGES**
The Meeting organisers are pleased to provide complimentary pages to authors of an oral presentation and/or poster presentation according to the following criteria:  
• Authors under 35 years old: 3 complimentary pages  
• Authors over 35 years old: 1 complimentary page

In order to benefit from these complimentary pages, it is mandatory that the first author of the manuscript is the one who presents the communication during the 2017 BANFF-SCT Joint Scientific Meeting. Proof of age must be sent to the Technical Secretariat, AOPC, before sending the manuscript. Failure to do so may result in the non application of this benefit.
2017 BANFF-SCT
Joint Scientific Meeting

Scientific programme
<table>
<thead>
<tr>
<th>Monday 27 March</th>
<th>Tuesday 28 March</th>
<th>Wednesday 29 March</th>
<th>Thursday 30 March</th>
<th>Friday 31 March</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>9.00 – 10.45</strong>&lt;br&gt;BANFF pre-meeting: New endpoints for next generation clinical trials</td>
<td><strong>9.00 – 10.30</strong>&lt;br&gt;BANFF working groups: Updates from BANFF working groups</td>
<td><strong>8.30 - 10.00</strong>&lt;br&gt;BANFF Plenary 1&lt;br&gt;The integrated diagnosis histology + DSA</td>
<td><strong>8.00 - 9.00</strong>&lt;br&gt;BANFF Symposium. The molecular microscope in routine Tx pathology</td>
<td><strong>9.00 - 11.00</strong>&lt;br&gt;SCT Plenary 5&lt;br&gt;The future of DCD in solid organ Tx</td>
</tr>
<tr>
<td>10.45 - 11.15 Coffee break</td>
<td>10.30 - 11.00 Coffee break</td>
<td><strong>10.00 - 10.30</strong>&lt;br&gt;Coffee break</td>
<td><strong>9.00 - 10.30</strong>&lt;br&gt;BANFF summary and closing remarks</td>
<td>11.00 - 11.30 Coffee break</td>
</tr>
<tr>
<td><strong>11.15 – 13.00</strong>&lt;br&gt;BANFF pre-meeting (continued)</td>
<td><strong>11.00 - 13.00</strong>&lt;br&gt;BANFF working groups (continued)</td>
<td><strong>10.30 - 11.30</strong>&lt;br&gt;SCT Plenary 1.&lt;br&gt;State of the art: Cellular repair of damaged organs</td>
<td><strong>10.30 - 11.00</strong>&lt;br&gt;Coffee break</td>
<td><strong>11.00 - 12.00</strong>&lt;br&gt;BANFF Plenary 2. Staging and grading of rejection: the need in the era of precision medicine</td>
</tr>
<tr>
<td><strong>13.00 - 14.00</strong>&lt;br&gt;Lunch break</td>
<td><strong>13.00 - 14.00</strong>&lt;br&gt;Lunch break</td>
<td><strong>11.30 - 12.00</strong>&lt;br&gt;Joint welcome session</td>
<td><strong>12.00 - 12.30</strong>&lt;br&gt;Joint Plenary. Abstracts 1</td>
<td>12.00 - 13.30 Coffee break</td>
</tr>
<tr>
<td><strong>14.00 - 15.00</strong>&lt;br&gt;Industry symposium 1</td>
<td><strong>14.00 - 15.00</strong>&lt;br&gt;Industry symposium 2</td>
<td><strong>12.00 - 13.00</strong>&lt;br&gt;Joint Plenary. Abstracts 2</td>
<td><strong>13.00 - 14.00</strong>&lt;br&gt;Industry symposium 3</td>
<td><strong>13.00 - 14.00</strong>&lt;br&gt;SCT Gold Medal BANFF-SCT closing</td>
</tr>
<tr>
<td><strong>15.00 - 17.30</strong>&lt;br&gt;BANFF pre-meeting (continued)</td>
<td><strong>15.00 - 18.30</strong>&lt;br&gt;BANFF Concurrent Kidney 1: The significance of IF-1a re-visiting TCMR and mixed rejection</td>
<td><strong>13.00 - 14.00</strong>&lt;br&gt;Industry symposium 3</td>
<td><strong>13.00 - 18.30</strong>&lt;br&gt;Joint Plenary. Abstracts 2</td>
<td><strong>13.00 - 14.00</strong>&lt;br&gt;SCT Gold Medal BANFF-SCT closing</td>
</tr>
<tr>
<td><strong>16.30 - 17.00</strong>&lt;br&gt;Coffee break</td>
<td><strong>16.30 - 17.00</strong>&lt;br&gt;Coffee break</td>
<td><strong>14.00 - 15.00</strong> Lunch break</td>
<td><strong>14.00 - 15.00</strong>&lt;br&gt;Lunch break</td>
<td><strong>14.00 - 15.00</strong>&lt;br&gt;Lunch break</td>
</tr>
<tr>
<td><strong>18.30 - 19.30</strong>&lt;br&gt;Joint poster session 1</td>
<td><strong>18.30 - 19.30</strong>&lt;br&gt;Joint poster session 1</td>
<td><strong>15.00 - 18.30</strong>&lt;br&gt;BANFF Concurrent Kidney 2</td>
<td><strong>15.00 - 18.30</strong>&lt;br&gt;BANFF Concurrent Kidney 2</td>
<td><strong>15.00 - 18.30</strong>&lt;br&gt;BANFF Concurrent Kidney 2</td>
</tr>
<tr>
<td><strong>19.00 - 20.00</strong>&lt;br&gt;BANFF BOT meeting</td>
<td><strong>19.00 - 20.00</strong>&lt;br&gt;BANFF BOT meeting</td>
<td><strong>15.00 - 18.30</strong>&lt;br&gt;BANFF Concurrent Liver 2</td>
<td><strong>15.00 - 18.30</strong>&lt;br&gt;BANFF Concurrent Liver 2</td>
<td><strong>20.30</strong>&lt;br&gt;Optional concert and cocktail dinner Fàbrica Moritz Barcelona</td>
</tr>
</tbody>
</table>

**OS = Oral Session**
MONDAY 27 MARCH

MONDAY

9.00 – 13.00  BANFF Pre-meeting
Paranimf Room

**New endpoints for next generation clinical trials**

**Chair:** Denis Glotz and Peter Nickerson

- Welcome and opening remarks. History and future of the BANFF Classification. Where the present lesion scoring criteria came from, and the continued need for ease of use and time efficiency
  Kim Solez, Alberta, Canada
- A tribute to Daniel R. Salomon (1953 - 2016)
  Kim Solez, Alberta, Canada
- DSA-monitoring as an end point
  Anat Tambur, Chicago, USA
- Refined histology scoring as a reliable endpoint
  Robert Colvin, Boston, USA

10.45 – 11.15  Coffee break

- The molecular microscope as an endpoint
  Philip Halloran, Alberta, Canada
- Clinical trials: the FDA unmet needs
  Mark Stegall, Rochester, USA
- Potential endpoints for response to treatment of ABMR in heart transplant recipients
  Luciano Potena, Bologna, Italy

13.00 – 14.00  Lunch break

14.00 – 15.00  Industry Symposium 1
Paranimf Room

15.00 – 17.30  BANFF Pre-meeting (continued)
Paranimf Room

**New endpoints for next generation clinical trials**

**Chair:** Denis Glotz and Peter Nickerson

- Potential endpoints for response to treatment of ABMR in liver transplant recipients
  Sandy Feng, San Francisco, USA
- Potential endpoints for response to treatment of ABMR in kidney transplant recipients
  Mark Stegall, Rochester, USA
- Optimizing statistical methods for generating robust endpoints
  Dorry Segev, Baltimore, USA
- Adopting a histo-immuno-clinico-laboratory composite endpoint: the iBox
  Alexandre Loupy, Paris, France
- Group discussion
TUESDAY

9.00 – 13.00
BANFF Working Groups

Updates from BANFF Working Groups

CHAIRS: Lorraine Racusen and Kim Solez

- Report on BANFF Foundation
  Michael Mengel, Edmonton, Canada
- Proposal for new BANFF Working Group: Transplantation HIV+ to HIV+
  Serena Bagnasco, Baltimore, USA
- EM scoring BWG
  Candice Roufosse, London, United Kingdom
- Highly sensitized BWG
  Ed Kraus, Rochester, USA

10.30 – 11.00
Coffee break

- Recurrent GN BWG
  Nada Alachkar, Baltimore, USA
- TMA in transplants BWG
  Marjan Afrouzian, Galveston, USA
- TCMR/borderline BWG
  Parmjeet Randhaw, Pittsburg, USA; Volker Nickeleit, Chapel Hill, USA
- Molecular BWG
  Michael Mengel, Edmonton, Canada

13.00 – 14.00
Lunch break

14.00 – 15.00
Industry Symposium 2

15.00 – 19.00
BANFF Concurrent

Kidney 1: The significance of i-IFTA revisiting TCMR and mixed rejection

CHAIRS: Ian Gibson and Candice Roufosse

- Chronic active TCMR: i-FTA, IATR, i, and the clinical implications
  Roslyn B. Mannon, Birmingham, USA
- Pathology of mixed rejection
  Ian Gibson, Manitoba, Canada
- Pathology of the late post-transplant kidney and the role of non T cells
  Lynn Cornell, Rochester, USA
- Molecular correlates of chronic TCMR
  Enver Akalin, New York, USA
16:30 – 17:00 Coffee break

- Do we need different scoring rules in early and late allograft biopsies? 
  Maarten Naesens, Leuven, Belgium
- iIFTA: significance and prognostic value 
  Clement Gosset, Paris, France
- Treatment of late and mixed rejection pathology 
  Brian Nankivell, Westmead, Australia
- Group discussion

15:00 – 19:00 BANFF Concurrent

Ramon i Cajal Room

**Lung-Antibody-mediated rejection, to be continued**

**CHAIRS**: David Hwang and Elizabeth Pavlisko

- The multidisciplinary approach to AMR in lung transplantation - reaching a consensus 
  Deborah Levine, San Antonio, USA
- Histopathology of AMR in the lung - Part 1 
  Fiorella Calabrese, Padova, Italy
- Histopathology of AMR in the lung - Part 2 
  Gerald Berry, Stanford, USA
- DSAs in lung transplantation 
  Adriana Zeevi, Pittsburg, USA

16:30 – 17:00 Coffee break

- Molecular signals and lung transplantation 
  Philip Halloran, Alberta, Canada
- Relevant endpoints in lung AMR treatment 
  Antoine Roux, Paris, France
- Therapeutic options and strategies – the old and the new 
  Ramsey Hachem, Missouri, USA
- Group discussion
15:00 – 19:00

**BANFF Concurrent**

**Liver 1**

**Chairs:** Anthony Jake Demetris and Stefan Hübscher

- Introduction – aims of liver sessions
  Anthony Jake Demetris, Pittsburg, USA

- Pathology of extra-corporeal perfusion of liver allografts – what to examine and how does it correlate with outcome
  Annette Gouw, Groningen, the Netherlands

- The prospects of extra-corporeal machine perfusion of donor livers
  Robert Porte, Groningen, the Netherlands

16:30 – 17:00

**Coffee break**

- Fibrosis and structural decline of liver allografts: what and how to measure and potential underlying causes
  Carla Venturi, Brussels, Belgium

- A pathologists guide to evaluating the long-surviving allograft: important features, stains, and approach to better understanding of chronic AMR
  Stefan Hübscher, Birmingham, United Kingdom

- Group Discussion
**WEDNESDAY**

**8.30 – 10.00**

**BANFF Plenary 1**

*The integrated diagnosis: histology + DSA*

**CHAIRS:** Philip Halloran and Christophe Legendre

- DSA positive and then - to biopsy or not?
  Peter Nickerson, Manitoba, Canada

- HLA DSA properties assessment in the real life: what does it add?
  Adriana Zeevi, Pittsburg, USA

- The value of DSA in managing ABMR diagnostic, prognostic, and response to therapy
  Carmen LeFaucheur, Paris, France

- Do we need DSA to diagnose ABMR? The pathologists view
  Mark Haas, Sherman Oaks, USA

---

**10.00 – 10.30**

Coffee break

---

**10.30 – 11.30**

**SCT Plenary 1**

*State of the art: cellular repair of damaged organs*

**CHAIRS:** Laura Lladó and Kim Solez

- Cell therapy in lung diseases
  Anna Serrano Mollar, Barcelona Spain

- Cell implantation after myocardial infarction: a 10-year experience from ICREC laboratory
  Santiago Roura, Barcelona, Spain

- Repopulating scaffoldings in kidney and liver
  Mireia Caralt, Barcelona, Spain

---

**11.30 – 12.00**

**Joint welcome session**

---

**12.00 – 13.00**

**Joint Plenary Abstracts 1**

**CHAIRS:** Ramón Charco and Brian Nankivell

*Determinants of severe fibrosis in kidney allograft: major impact of circulating donor specific Anti-HLA antibodies*

C. Gosset¹, D. Viglietti², M. Rabant³, D. Denis⁴, C. Legendre⁵,
J.P. Duong Van-Huyen³, A. Loupy², C. Lefaucheur²

1: Pathology, Saint-Louis Hospital, Paris, France. 2: Paris Translational Research Center for Organ Transplantation, Paris, France.
3: Pathology, Necker Hospital, Paris, France. 4: Nephrology and Kidney Transplantation, Saint-Louis Hospital, Paris, France. 5: Nephrology and Kidney Transplantation, Necker Hospital, Paris, France
JPA-2 Banff v3 Arteritis: reappraisal of clinicopathologic characteristics under contemporary immunosuppression
A. Farris, Clifford Sullivan, T. Rogers, R. Bray, H. Gebel, C. Ellis
Department of Pathology, Emory University, Atlanta, United States

JPA-3 Gene expression during development of chronic antibody mediated rejection in renal allografts from non-human primates: validation of markers used in humans and sequential changes in protocol biopsies
B. Adam1, R.N. Smith2, I.A. Rosales2, B. Afzali1, T. Oura3, A.B. Cosimi3, T. Kawai3, R.B. Colvin2, M. Mengel1
1: Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Canada. 2: Department of Pathology, Harvard Medical School and Massachusetts General Hospital, Boston, USA. 3: Department of Surgery, Harvard Medical School and Massachusetts General Hospital, Boston, USA

JPA-4 Tacrolimus and mycophenolate mofetil exposure and subclinical inflammation in low immunological risk renal transplants
I. Torres1, C. Dörje2, F. Moreso1, A. Asberg2, M. Vidal1, C. Garcia Carro1, F.P. Reinholt2, E. Castella1, M. Salcedo1, J. Sellares1, M.A. Azancot1, M. Perello1, X. Guri1, H. Holdaas2, A. Reisaeter2, D. Seron1
1: Nephrology, Hospital Universitari Vall d’Hebron, Barcelona, Spain. 2: Nephrology, Oslo University Hospital Rikshospitalet, Oslo, Norway

JPA-5 Noninvasive assessment of liver fibrosis and portal hypertension after viral eradication in post-transplant hepatitis C
E. Mauro1, G. Crespo1, M. Londoño1, A. Diaz2, P. Ruiz1, L. Sastre1, J. Lombardo1, J. Aguirre1, J. Colmenero1, M. Navasa1
1: Liver Transplant Unit, 2: Pathology Department, Hospital Clinic, IDIBAPS, CIBERehd, Barcelona, Spain

JPA-6 Outcomes of different cross-match techniques pre-transplantation among HLA-incompatible living kidney transplant patients
E. Melili1, M. Meneghini1, I. Revuelta2, F. Diekmann2, O. Taco1, J. Cruzado1, E. Rigol3, J. Grinyo1, J. Martorell3, O. Bestard1
1: Kidney Transplant Unit, Nephrology Department, Bellvitge University Hospital, IDIBELL, Barcelona, Spain. 2: Kidney Transplant Unit, Nephrology Department, Clinic University Hospital, Barcelona, Spain. 3: Immunology Department, Clinic University Hospital, Barcelona, Spain

13.00 – 14.00 Industry Symposium 3
Aula Magna Room

14.00 – 15.00 Lunch break
### SCT Plenary 2

**Key issues in clinical trials in solid organ transplantation**

**Chair:** Denis Glotz and Frederic Oppenheimer

- **The challenge of therapeutic innovation in organ transplantation**
  Josep M. Grinyó, Barcelona, Spain

- **Methodological constraints in the design of clinical trials**
  Daniel Serón, Barcelona, Spain

- **New endpoints for new generation clinical trials: a summary of Banff proposals**
  Julio Pascual, Barcelona, Spain

- **Clinical trials investment. The industry point of view**
  Guido Junge, Basel, Switzerland

### 15.00 - 16.30

**Paranimf Room**

**SCT Plenary 2**

### 16.30 - 17.00

**Coffee break**

### 17.00 - 18.30

**Paranimf Room**

**SCT Oral Session 1**

**Experimental and immunology aspects**

**Chair:** Lluís Guirado and Eduard Palou

**OS1-1**

**Monitoring miRNA-155-5p expression as biomarker of prognosis and diagnosis of acute rejection in liver and renal transplant recipients**

O. Millan¹, I. Aliart¹, K. Budde², B. Bardají³, G. Crespo⁴, L. Guirado³, M. Navasa⁴, L. Orts⁴, P. Ruiz⁴, C. Sommerer⁵, M. Brunet¹

1: Pharmacology and Toxicology Laboratory, CDB, IDIBAPS, CIBERehd, Hospital Clinic of Barcelona, University of Barcelona, Spain.

2: Medizinische KlinikmitSchwerpunkt Nephrologie, Charité Universitätsmedizin, Berlin, Germany.

3: Renal Transplant Unit, Nephrology Department, Fundació Puigvert, Barcelona, Spain.

4: Liver Unit, Hospital Clinic, IDIBAPS and CIBERehd, University of Barcelona, Spain.

5: Department of Nephrology, University of Heidelberg, University Hospital Heidelberg and Mannheim, Heidelberg, Germany

**OS1-2**

**Bone marrow mesenchymal stem cells but not their extracellular vesicles improve kidney graft outcome in a model of chronic mixed cellular and humoral rejection in rat**

M.J. Ramirez Bajo¹, J. Rovira¹, M. Lazo-Rodriguez², E. Banon-Maneus¹, V. Tubita², D. Moya-Rull¹, N. Hierro-Garcia², I. Revuelta³, P. Ventura³, F. Oppenheimer³, J.M. Campistol³, F. Diekmann³

1: Laboratori Experimental de Nefrologia I Trasplantament (LENIT), Fundació Clínic per la Recerca Biomèdica (FCRB), Barcelona, Spain.

2: Laboratori Experimental de Nefrologia I Trasplantament (LENIT), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

3: Departament de Nefrologia i Transplantament Renal, Institut Clínic de Nefrologia i Urologia (ICNU), Hospital Clínic (HC), Barcelona, Spain
MiRNA 181a and 148a plasma levels during acute cellular rejection in liver transplantation

P. Ruiz¹, O. Millán², L. Orts¹, I. Aliart², A. Díaz³, L. Sastre¹, J. Colmenero¹, G. Crespo¹, M. Brunet², M. Navasa¹

1: Liver Transplant Unit, Hospital Clinic, IDIBAPS, CIBERehd, Barcelona, Spain. 2: Pharmacology and Toxicology, Hospital Clinic, IDIBAPS, CIBERehd, Barcelona, Spain. 3: Pathology Department, Hospital Clinic, Barcelona, Spain

Impact of the new evaluation of glomerulitis according to Banff 2013 classification of antibody-mediated rejection

J. Gimeno¹, D. Redondo², M.J. Pérez-Saez², D. Naranjo-Hans¹, M. Mir², J. Pascual², M. Crespo²

1: Department of Pathology, 2: Department of Nephrology, Hospital del Mar, Barcelona, Spain

Complement-binding donor-specific antibodies, acute rejection and kidney graft loss: C3d better than C1q

M. Crespo¹, D. Redondo¹, M.J. Pérez-Sáez¹, J. Gimeno², C. García³, M. Mir¹, J.J. Hernández³, J. Pascual¹

1: Department of Nephrology, 2: Department of Pathology, 3: Reference Laboratory, Hospital del Mar, Barcelona, Spain

Outcomes of kidney transplantation in patients with preformed, cleared or persistent, HLA donor-specific antibodies

D. Redondo¹, M.J. Pérez-Sáez¹, M. Mir¹, J. Gimeno², C. García³, J.J. Hernández³, J. Yélamos⁴, J. Pascual¹

1: Department of Nephrology, 2: Department of Pathology, 3: Reference Laboratory, 4: Dept of Immunology, Hospital del Mar, Barcelona, Spain

15.00 – 18.30
Aula 0.1 Room

BANFF Concurrent Pancreas

CHAIR: Cinthia Drachenberg and Diego Cantarovich

- Pancreas perfusion with hypothermic machine: pancreas and duodenal histology up to 24 hours
  Julien Branchereau, Nantes, France

- Effect of immunosuppressive therapies on transplanted islets and pancreas
  Javier Triñanes Ramos, Leiden, the Netherlands

- Outcome of pancreas transplantation alone with portal venous drainage vs. systemic venous drainage
  Stephen Bartlett, Baltimore, USA

- Vascular remodelling following whole pancreas transplantation
  Steven White, New Castle, United Kingdom
16.30 – 17.00 Coffee break

**BANFF CONCURRENT, PANCREAS, CONTINUED**

- Impact of BK infection in pancreas transplant recipients
  Maria Fernanda Toniolo, Buenos Aires, Argentina
- Histology of refractory rejection
  John Papadimitriou, Meriland, USA
- Comparison between rejection in pancreas and kidney biopsies in SPK patients with graft dysfunction.
  Pablo Uva, Buenos Aires, Argentina
- Case presentation
  Diego Cantarovich, Nantes, France
- Group Discussion

15.00 – 16.30

**BANFF Concurrent**

**Heart**

CHAIRS: Annalisa Angelini and Gerald Berry

- The contribution of the pathologist to expand the donor pool in cardiac transplantation
  Ornella Leone, Bologna, Italy
- The multifaceted pathologies of CAV
  Gregory A. Fishbein, Los Angeles, USA
- Vasculitis process at the base of CAV
  Marny Fedrigo, Padova, Italy
- Immunopathology of CAV
  Manon Huibers, Utrecht, the Netherlands
- Chronic injury to the microcirculation in EMB
  Dylan Miller, Salt Lake City, USA; Patricia Revelo, Salt Lake City, USA

16.30 – 17.00 Coffee break

17.00 – 18.30

**BANFF Concurrent**

**Heart**

CHAIRS: Ornella Leone and Dylan Miller

- cfDNA in heart transplantation injury to the microcirculation in EMB
  Kiran Khush, Stanford, USA
- Gene expression on FFPE EMB for the diagnosis of rejection in heart transplantation
  Michael Mengel, Edmonton, Canada
- MicroRNA on FFPE EMB for the diagnosis of rejection in heart transplantation
  Annalisa Angelini, Padova, Italy
- Does chronic ABMR exist in cardiac transplantation?
  Patrick Bruneval, Paris, France
- Towards an uniform terminology for the pathology of CAV
  Gerald Berry, Stanford, USA
- Panel discussion on CAV terminology/pathophysiology. Towards an uniform terminology for the pathology of CAV
  Discussion leader Gerald Berry, Stanford, USA

15.00 – 18.30  **BANFF Concurrent**
**VCA**
CHAIRS: Linda Cendales and Brad Farris
- Chronic rejection in VCA
  Jean Kanitakis, Lyon, France
- VCA skin scoring system in a preclinical model
  Ivy Rosales, Boston, USA
- The role of immunohistochemistry and additional tools in the diagnosis of VCA skin rejection
  David Elder, Philadelphia, USA
- Skin containing VCA as a monitoring tool for intestinal transplantation
  Annemarie Weissenbacher, Oxford, United Kingdom
- Uterus transplant rejection: a provisional scoring system for rejection
  Carl Johan Molne, Göteborg, Sweden
- Vascular changes in a transplanted organ
  Louis DiBernardo, Durham, USA
- Discussion and Next Steps

18.30 – 19.30  **Joint Poster Session 1**
THURSDAY

8.00 - 9.00
Paranimf Room

BANFF Symposium

The molecular microscope in routine transplantation pathology
CHAIRS: Mark Haas and Alexandre Loupy

- Centralized molecular diagnostics: methods, platforms, pitfalls
  Philip Halloran, Alberta, Canada
- Decentralized molecular diagnostics: Pros and Cons
  Robert Colvin, Boston, USA
- Panel Discussion

9.00 - 10.30
Paranimf Room

SCT Plenary 3

How to increase the donor pool
CHAIRS: Julio Pascual and Teresa Pont

- The changing scenario for organ donation
  Elisabeth Coll, Madrid, Spain
- Donor quality assessment
  Francesc Moreso, Barcelona, Spain
- Omics to assess quality of donated organs
  Rainer Oberbauer, Vienna, Austria

10.30 - 11.00
Coffee break

11.00 - 12.00
Paranimf Room

BANFF Plenary 2

Staging and grading of rejection: the need in the era of precision medicine
CHAIRS: Robert Colvin and Philip Halloran

- IgA nephropathy: morphologic findings associated with disease progression and therapeutic response. A working group approach
  Mark Haas, Sherman Oaks, USA
- Grading of microcirculation inflammation in heart allografts
  Jean-Paul Duong Van Huyen, Paris, France
- Vascularized allograft biopsies revisited
  Linda Cendales, Durham, USA

12.00 - 13.00
Paranimf Room

Joint Plenary Abstracts 2

CHAIRS: Josep Maria Cruzado and Michael Mengel

JPA2-1

Differential profile of activated regulatory T cell subsets and microRNAs in tolerant liver transplant recipients

A. Baroja-Mazo\textsuperscript{1}, B. Revilla-Nuin\textsuperscript{1}, L. Martinez-Alarcon\textsuperscript{1}, J.I. Herrero\textsuperscript{2}, C. Martinez-Caceres\textsuperscript{1}, P. Ramírez\textsuperscript{1}, J.A. Pons\textsuperscript{1}

1: Digestive Surgery and Organ Solid Transplantation, Murcia’s Biohealth Research Institute –Virgen de la Arrixaca, El Palmar, Murcia.
2: Liver Unit, Clínica Universidad de Navarra, Pamplona
**JPA2-2**

**KL-6 as a potential biomarker to differentiate chronic allograft dysfunction phenotypes in lung transplantation**


1: Pulmonology, 2: Thoracic Surgery, Hospital Universitari Vall d’Hebron, Barcelona

**JPA2-3**

**Circulating donor-specific (D-SP) memory B cells (MBC) discriminates kidney transplant patients with histological lesions of ABMR in absence of circulating DSA**


1: Experimental Nephrology, IDIBELL, Hospitalet de Llobregat. 2: Kidney Transplant Unit, Nephrology department, Bellvitge University Hospital, Barcelona. 3: Immunogenetics Laboratory, Hospital Clínic. Barcelona

**JPA2-4**

**Immunopathological features of human chronic skin allograft rejection**

S. Rotman, N. Koch, I. Ivy, R. Robert, V. Vincent, W. Wassim, M. Manuel

1: Pathology, University Hospital of Lausanne, Lausanne, Switzerland. 2: University Hospital of Lausanne. 3: Pathology-MGH-Boston

**JPA2-5**

**Digital image analysis in assessment of fibrosis in pediatric liver allografts**

A. Kats, R.T. Fischer, R.J. Hendrickson, J.F. Daniel, S. Foster, W.S. Andrews

1: Dept of Pathology and Laboratory Medicine, 2: Dept of Gastroenterology, 3: Dept of Surgery, Children’s Mercy Hospital, Kansas City, MO 64108, 4: Medical Student G2, Kansas University SOM, Kansas City, KS 66160

**JPA2-6**

**Use of NanoString nCounter technology to assess C4d positive biopsies with no histological evidence of inflammation**


1: Centre for Complement & Inflammation Research (CCIR), Imperial College London, UK. 2: Imperial College Kidney and Transplant Institute, Hammersmith Hospital, London, UK. 3: King Saud University, Riyadh, Kingdom of Saudi Arabia. 4: Department of Cellular Pathology, Hammersmith Hospital, London, UK

13.00 – 14.00 Industry symposium 4

Paranimf Room

14.00 – 15.00 Lunch break
SCT Plenary 4

**Precision medicine in solid organ transplantation**

**CHAIRS:** Fritz Diekmann and Nicolás Manito

- Pharmacogenetics to tailor drug exposure and outcomes in kidney transplant
  Dennis Hesselink, Rotterdam, Holand
- Monitoring memory B Cells responses in transplantation
  Oriol Bestard, Barcelona, Spain
- State of the art: Finger prints of tolerance
  Maria Hernández, London, United Kingdom

**16.00 – 16.30** Coffee break

- Personalized medicine in liver transplantation
  Miquel Navasa, Barcelona, Spain
- Measuring patients alloreactivity to personalize treatment
  Mercè Brunet, Barcelona, Spain

SCT: Oral Session 2

**Update in organ donation**

**CHAIRS:** David Paredes and Alberto Sandiumenge

**OS2-1**

**Long-term evolution of living kidney donors in Catalonia**

E.A. Florit¹, R. Jurado Tapiador¹, E. Arcos Fuster², J. Comas Farnés², S. Gil-Vernet³, L. Guirado Perich⁴, R. Lauzurica⁵, F. Moreso⁶, J. Pascual⁷, J. Tort Bardolet², F. Diekmann¹

1: ICNU, Hospital Clinic, 2: Organización Catalana de Trasplante, 3: Hospital Universitario de Bellvitge, 4: Fundación Puigvert, 5: Hospital Universitario Germans Trias i Pujol, 6: Hospital Vall d’Hebron, 7: Hospital del Mar, Barcelona

**OS2-2**

**Factors associated with infra-compensation of the remaining kidney after total nephrectomy after donation**

C. Burballa¹, M. Crespo¹, D. Redondo-Pachón¹, M.J. Pérez-Sáez¹, M. Mir¹, L. Fumadó², A. Francés², J.M. Puig¹, L. Cecchini², J. Pascual¹

1: Department of Nephrology, 2: Department of Urology, Hospital del Mar, Barcelona

**OS2-3**

**Survival comparison among kidney transplant recipients from deceased donors over 80 years and patients on dialysis awaiting transplantation**

E. Arcos¹, M.J. Pérez Sáez², J. Comas¹, J. Pascual²

1: Registre de Malalts Renals de Catalunya. Organització Catalana de Trasplantaments. 2: Department of Nephrology, Hospital del Mar, Barcelona
0S2-4  Relative's perception about the tissue donation process: result of post donation phone survey
R. Roque, C. Rodríguez-Villar, D. Paredes, A. Ruiz, R. Gelpi, J. Garcia, S. Rodríguez, R. Adalia
Sección de Donación y Coordinación de Trasplantes, Hospital Clínic, Universidad de Barcelona

0S2-5  Strategy to assess extended donor criteria renal suitability: a paired kidney study comparing hypothermic pulsatile perfusion machine versus cold storage
D. Paredes¹, A. Sanchez², A. Ruiz¹, C. Rodriguez-Villar¹, R. Roque¹, R. Gelpi¹, J. Garcia¹, L. Peri³, F. Diekmann², F. Oppenheimer², R. Adalia¹
1: Donation and Transplant Coordination Unit, 2: Kidney Transplant Unit, 3: Urology Department. Hospital Clinic, University of Barcelona

0S2-6  Effect of the lung allocate score in postoperative lung transplantation in a university hospital
I. Bello¹, M. Deu¹, L. Romero¹, A. Jauregui¹, J. Pérez¹, J.M. Ochoa¹, V. Díaz¹, L. Sánchez¹, F. Ascanio¹, C. Berastegui², A. Sandiumenge³, D. Ruiz⁴, C. Laborda⁵, J. Solé¹
1: Thoracic Surgery, 2: Pneumology, 3: Transplant Coordination, 4: Anesthesiology, 5: Intensive Care, Vall d’Hebron University Hospital, Barcelona

0S2-7  Impact on the perception and attitudes of an on-line educative action about limitation of life sustaining treatment (LLST), donation after brain death (DBD) and donation after circulatory death (DCD) on Spanish critical care doctors
A. Sandiumenge¹, X. Montaña-Carreras², M. Lomer³, J.D. Molina², M. Bodí⁴, N. Masnou⁵, T. Pont¹
1: Transplant Coordination, University Hospital Vall d’Hebron, Barcelona. 2: Magnore e-Health and e-learning Services, Tarragona. 3: PhD student. Nursing University Rovira i Virgili. 4: Intensive Care Dept, University Hospital Joan XXIII, Tarragona. 5: Transplant Coordination, University Hospital Josep Trueta, Girona
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Details</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>15.00 – 19.00</strong></td>
<td><strong>BANFF concurrent</strong></td>
</tr>
<tr>
<td>Aula Magna Room</td>
<td><strong>Kidney 2</strong></td>
</tr>
<tr>
<td></td>
<td><em>CHAIRS:</em> Mark Haas and Alexandre Loupy</td>
</tr>
<tr>
<td></td>
<td>- Final decision on PVN scoring</td>
</tr>
<tr>
<td></td>
<td>Volker Nickeleit, Chapel Hill, USA</td>
</tr>
<tr>
<td></td>
<td>- EM scoring system - are we ready for adoption into the classification?</td>
</tr>
<tr>
<td></td>
<td>Harsharan Singh, Chapel Hill, USA</td>
</tr>
<tr>
<td></td>
<td>- Standardized Banff scoring - A web-based approach</td>
</tr>
<tr>
<td></td>
<td>Jan Ulrich Becker, Cologne, USA</td>
</tr>
<tr>
<td><strong>16.00 – 16.30</strong></td>
<td><strong>Coffee break</strong></td>
</tr>
<tr>
<td></td>
<td>- Scoring of i-IFTA: potential rules and role in chronic TCMR</td>
</tr>
<tr>
<td></td>
<td>Parmjeet Randhawa, Pittsburg, USA</td>
</tr>
<tr>
<td></td>
<td>- Group discussion</td>
</tr>
<tr>
<td><strong>15.00 – 19.00</strong></td>
<td><strong>BANFF concurrent</strong></td>
</tr>
<tr>
<td>Ramon i Cajal Room</td>
<td><strong>Liver 2</strong></td>
</tr>
<tr>
<td></td>
<td><em>CHAIRS:</em> Chris Bellamy and Sandy Feng</td>
</tr>
<tr>
<td></td>
<td>- Serum DSA in long-surviving liver allograft recipients: an algorithmic approach to determine potential clinical significance</td>
</tr>
<tr>
<td></td>
<td>Sandy Feng, San Francisco, USA</td>
</tr>
<tr>
<td></td>
<td>- Focusing the ‘molecular microscope’ on liver allografts: integration of genomics and tissue pathology</td>
</tr>
<tr>
<td></td>
<td>Alberto Sánchez-Fueyo, London, United Kingdom</td>
</tr>
<tr>
<td><strong>16.00 – 16.30</strong></td>
<td><strong>Coffee break</strong></td>
</tr>
<tr>
<td></td>
<td>- Subclinical liver allograft rejection and ‘tolerance-related’ liver infiltrates</td>
</tr>
<tr>
<td></td>
<td>Richard Taubert, Hannover, Germany</td>
</tr>
<tr>
<td></td>
<td>- Group discussion</td>
</tr>
<tr>
<td><strong>19.00 – 20.00</strong></td>
<td><strong>Joint Poster Session 2</strong></td>
</tr>
</tbody>
</table>
FRIDAY

9.00 – 11.00
Paranimf Room

BANFF Summary and closing remarks
CHAIR: Kim Solez

- Kidney summary
  Mark Haas, Sherman Oaks, USA
- Liver summary
  Anthony Jake Demetris, Pittsburg, USA
- Pancreas summary
  Cinthia Drachenberg, Baltimore, USA
- Heart summary
  Patrick Burneval, Paris, France

9.00 – 11.00
Aula Magna Room

SCT Plenary 5
The future of DCD in solid organ transplantation
CHAIRS: Marta Crespo and Núria Masnou

- DCD donors in Spain: pearls and pitfalls
  Elisabeth Coll, Madrid, Spain
- Risk factors associated with DCD kidney function and survival
  José Maria Portolés, Madrid, Spain
- Will normothermic perfusion become the new standard for the maintenance of DCD donors?
  - Thoracic normothermic perfusion
    Stephen Large, Cambridge, United Kingdom
  - Abdominal normothermic perfusion
    Constantino Fondevila, Barcelona, Spain
- Update on the results of recent clinical trials on organ machine perfusion prior to transplantation:
  - Lung
    Irene Bello, Barcelona, Spain
  - Liver
    Rubén Ciria, Córdoba, Spain

11.00 – 11.30  Coffee break
11.30 – 13.00  
Paranimf Room  
**BANFF summary**  
*CHAIRS:* Kim Solez  
- Lung summary  
  David Hwang, Toronto, Canada  
- Vascularized Composite Allografts summary  
  Linda Cendales, Durham, USA  
- Closing remarks  
  Kim Solez, Alberta, Canada

11:30 – 13:00  
Aula Magna Room  
**SCT Oral Session 3**  
**Hot topics in outcomes after solid organ transplantation**  
*CHAIRS:* Gonzalo Crespo and Antonio Román

**OS3-1**  
*Donor mannose-binding lectin (MBL) gene polymorphisms increases the risk of severe bacterial infections after liver transplantation*  
J. Lombardo¹, G. Sanclemente², J. Colmenero¹, M. Español³, P. Ruiz¹, G. Crespo¹, L. Sastre¹, A. Moreno², F. Lozano³, M. Navasa¹  
¹: Liver Transplant Unit, Hospital Clínic, IDIBAPS, CIBERehd, Barcelona.  
²: Infectious Diseases, Hospital Clínic, Barcelona.  
³: IDIBAPS area 1, Hospital Clínic, Barcelona

**OS3-2**  
*Short and long-term outcomes in liver transplant of arterial reconstruction on the recipient’s splenic artery due to inadequacy of the hepatic artery. Experience in our center after 1500 liver transplants*  
Liver Transplant Unit, University Hospital of Bellvitge, Barcelona

**OS3-3**  
*Endoscopy vs surgery for the treatment of anastomotic biliary stricture following deceased donor liver transplantation*  
K. Mils¹, L. Lladó¹, C. Ballellas¹, J. B. Gornals², C. Consiglieri², E. Gonzalez-Vilasartana¹, J. Busquets¹, E. Ramos¹, J. Fabregat¹  
¹: Unitat de Cirurgia Hepatobiliopancreatica i Trasplantament.  
²: Aparell Digestiu, Hospital Universitari de Bellvitge, l’Hospital de Llobregat

**OS3-4**  
*Impact of sustained virological response on liver fibrosis in recurrent hepatitis C after liver transplantation*  
E. Mauro¹, G. Crespo¹, M. C. Londoño¹, A. Diaz², L. Sastre¹, P. Ruiz¹, J. Colmenero¹, X. Forns², M. Brunet³, M. Navasa¹  
¹: Liver Transplant Unit, ²: Pathology Department, ³: Pharmacology and Toxicology, Hospital Clinic, IDIBAPS, CIBERehd, Barcelona
**0S3-5**  
**Incidence of de novo tumors after liver transplantation and influence on survival of conversion to mTOR inhibitors**  
Liver Transplant Unit, Hospital Universitario Bellvitge, l’Hospitalet de Llobregat

**0S3-6**  
**Incidence of non-skin cancer after kidney transplantation: risk factors and long term impact**  
A. Buxeda i Porras, D. Redondo, M. J. Pérez, A. Bartolomé, M. Mir, A. Pascual, A. Sans, M. Crespo, J. Pascual  
Department of Nephrology, Hospital del Mar, Barcelona

**0S3-7**  
**Adaptive NKG2C+ NK cell response and the risk of cytomegalovirus infection in kidney transplant recipients**  
D. Redondo¹, M. Crespo¹, J. Yélamos², A. Muntasell², M. J. Pérez-Sáez¹, C. Vilches³, J. Pascual¹, M. López-Botet²  
¹: Department of Nephrology, Hospital del Mar, Barcelona. ²: Department of Immunology, Hospital del Mar, Barcelona. ³: Department of Immunology, Hospital Puerta de Hierro, Madrid

**0S3-8**  
**Impact of rATG on CMV-specific memory T cell homeostatic proliferation and its implication in CMV infection**  
M. Jarque¹, S. Luque¹, E. Crespo¹, E. Melilli², J. Torras², J. M. Grinyó², O. Bestard²  
¹: Experimental Nephrology Laboratory, IDIBELL, Barcelona. ²: Kidney Transplant Unit, Nephrology Department, Bellvitge University Hospital, Barcelona

13:00 – 13:30  
Paranimf Room  
**Joint Session BANFF-SCT**  
**Gold Medal award of the Catalan Transplantation Society**  
**Chairs:** Antonio Román and Daniel Serón

13:30 – 14:00  
Paranimf Room  
**Closing**
2017 BANFF-SCT
Joint Scientific Meeting

Posters
Wednesday 29 March, 18.30 - 19.30

**Joint Poster Session 1**
P1 - P38

Thursday 30 March, 18.30 - 19.30

**Joint Poster Session 2**
P39 - P78
Joint Poster Session 1

P-1 Isolated crystalloid podocytopathy with focal segmental glomerulosclerosis in renal allograft: an unusual presentation of post-transplant monoclonal gammopathy of renal significance
A. Yang¹, C. Loong², N. Lin², C. Yang³
1: Department of Pathology and Laboratory Medicine, 2: Department of Transplantation Surgery, 3: Division of Nephrology, Department of Internal Medicine, Taipei Veterans General Hospital, Taipei, Taiwan

P-2 Nephrotic range proteinuria in renal transplantation: clinical and histologic correlates in a 10-year retrospective study
R. Leal¹, H. Pinto¹, A. Galvão¹, L. Santos¹, C. Romãozinho¹, F. Macário¹, R. Alves¹, V. Sousa², C. Marinho², L. Prado e Castro¹, A. Figueiredo³
1: Nephrology, 2: Anatomic Pathology. 3: Urology and Renal Transplantation, Centro Hospitalar e Universitário de Coimbra, Portugal

P-3 Vasa Recta Hyalinosis reflects severe arteriopathy extending to efferent arteriolo in the latter phase of allografted kidney biopsy
H. Oguchi¹, K. Sakai¹, Y. Yamauchi², T. Kawamura¹, M. Muramatsu¹, I. Toshihiro¹, H. Youji¹, T. Yusuke¹, N. Hiroshi¹, Y. Takashi¹, O. Yasushi¹, H. Yuko¹, S. Seichiro¹, M. Tetsuo³, N. Tetsuo⁴, S. Kazutoshi⁴, A. Atushi¹
1: Nephrology, Toho University School of Medicine, Tokyo, Japan. 2: Yamaguchi Pathology Institution. 3: Toho University School of Medicine, Pathology. 4: Toho University School of Medicine, Hospital Pathology

P-4 HMGB1 increase the survival pathways to protect steatotic and non-steatotic liver transplantation from cadaveric donors
E. N. Negrete-Sánchez¹, C. G. Avalos de León¹, M. B. Jiménez-Castro², A. Casillas-Ramirez³, M. E. Cornide-Petronio¹, J. Gulfo⁴, A. I. Alvarez-Mercado¹, E. Bujaldon¹, J. Gracia-Sancho⁵, J. Rodés¹, C. Peralta⁶
1: Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona. 2: Transplant Biomedical S.L. IDIBAPS, Barcelona. 3: Hospital Regional de Alta Especialidad de Ciudad Victoria, Facultad de Medicina e Ingeniería en Sistemas Computacionales de Matamoros, Universidad Autónoma de Tamaulipas, México. 4: Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERHD), Barcelona. 5: Barcelona Hepatic Hemodynamic Laboratory, IDIBAPS, CIBERHD, Barcelona. 6: Transplant Biomedicals S.L. IDIBAPS, CIBERHD, Barcelona
P-5  **Pathological assessment of allograft nephrectomy; an Iranian experience**

D. Taheri¹, M. Ghavami¹, S. Dolatkhah², M. Fesharakizadeh³, S. Fesharakizadeh⁴, P. Mahzouni¹, A. Atapour⁵, M. Hashemi⁶, H. Mazdak⁷, R. Salajegheh⁸

1: Pathology, Isfahan University of Medical Sciences, Isfahan, Iran.
2: Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
3: Department of Surgery, Najaf Abad branch of Islamic Azad University, Isfahan, Iran.
4: Department of Pathology, Isfahan University of Medical Sciences, Isfahan, Iran.
5: Department of Pathology, San Francisco state university, San Francisco, USA.
6: Department of Pathology, Isfahan University of Medical Sciences, Isfahan, Iran.
7: Department of Pathology, Isfahan University of Medical Sciences, Isfahan, Iran.
8: Faculty of Medicine, Yazd University of Medical Sciences, Isfahan, Iran.

P-6  **Benign clinical course and histological change of living-related renal transplant from the donor with membranous nephropathy**

S. Hara¹, Y. Takahashi², M. Kawano¹

1: Internal Medicine, Kanazawa University Graduate School of Medicine, Kanazawa, Japan.
2: Internal Medicine, Takaoka City Hospital, Takaoka, Japan.

P-9  **The histomorphological spectrum of restrictive chronic lung allograft dysfunction (RCLAD): implications for its etiopathogenesis and evidence for prognostic patterns of fibrosis**

J. von der Thüsen¹, E. Vandermeulen², R. Vos², B. Weynand³, E. Verbeken³, S. Verleden²

1: Pathology, Erasmus MC, Rotterdam, Netherlands.
2: Lung Transplant Unit, Department of Clinical and Experimental Medicine, KU Leuven, Leuven, Belgium.
3: Pathology, UZ Gasthuisberg, Leuven, Belgium.

P-10  **Incidence of infectious disease and malignancies after Rituximab therapy in kidney transplant recipients - results from a cohort in Germany (GRAID)**

E. Schrezenmeier¹, F. Halleck¹, O. Staekl¹, T. Dörner¹, D. Duerr¹, L. Lehrner¹, D. Khadzhynov¹, B. Budde¹

1: Nephrology, Charité Universitätsmedizin Berlin.
2: Rheumatology, Charité Universitätsmedizin, Berlin, Germany.

P-11  **Gene expression measurement during swine lung ex vivo perfusion: molecular quantification of donor lung injury and repair**

B. Adam¹, P. Dromparis¹, S. Wagner¹, N. Aboelnazar², S. Himmat², J. Luc², D. Freed², J. Nagendran², M. Mengel¹

1: Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Canada.
2: Department of Surgery, Division of Cardiac Surgery, University of Alberta, Edmonton, Canada.
P-12  
**JAK3 inhibition prolongs renal allograft survival in a model of chronic mixed cellular and humoral rejection in rat**


1: Laboratori Experimental de Nefrologia i Trasplantament (LENIT), Fundació Clínic per a la Recerca Biomèdica, Barcelona. 2: Laboratori Experimental de Nefrologia i Trasplantament (LENIT), IDIBAPS, Barcelona. 3: Departament de Nefrologia i Trasplantament Renal, Hospital Clínic, Barcelona

---

P-13  
**Prophylaxis with Enoxaparin for prevention of venous thromboembolism after lung transplantation**


Lung Transplant Unit, Hospital Universitari Vall d’Hebrón, Barcelona

---

P-14  
**Post-transplant IGA nephropathy: experience of 20 cases from a tertiary care center in India**

M. Jain, D. S. Bhaduaria, R. K. Sharma, V. Agrawal, N. Prasad

1: Department of Pathology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India. 2: Department of Nephrology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India

---

P-15  
**Donor specific antibodies in long term survivors after double-lung transplant**


1: Servicio de Neumología, Hospital Universitario Vall d’Hebron, Universidad Autónoma de Barcelona, Barcelona. Ciber de enfermedades Respiratorias (CibeRes), Instituto de Salud Carlos III, Madrid. 2: Servicio de Neumología, Hospital Universitario Vall d’Hebron, Barcelona. 3: Servicio de Neumología, Hospital Universitario La Fe, Valencia. 4: Servicio de Neumología, Hospital Universitario Marqués de Valdecilla, Santander. 5: Servicio de Cirugía Torácica, Hospital Juan Canalejo, A Coruña. 6: Servicio de Neumología, Hospital Universitario Puerta de Hierro, Madrid. 7: Unidades de Gestión Clínica de Neumología, Cirugía Torácica y Trasplante Pulmonar, Hospital Universitario Reina Sofía, Córdoba. 8: Servicio de Inmunología, Centro de Diagnóstico Biomédico (CDB), Hospital Clínic Barcelona, Barcelona
P-16  **Is the immunosuppressant therapy altering the iron metabolism in graft kidney?**

E. Banon-Maneus¹, J. Rovira¹, I. Revuelta², L.F. Quintana³, M. Lazo-Rodríguez³, M.J. Ramírez-Bajo¹, D. Moya-Rull¹, N. Hierro-Garcia², V. Tubita³, P. Ventura-Aguiar², F. Oppneheimer², F. Diekmann², J.M. Campistol²

1: Laboratori Experimental de Nefrologia i Trasplantament (LENIT), Fundació Clínica per a la Recerca Biomèdica, Barcelona.  2: Departament de Nefrologia i Trasplantament Renal, Institut Clínic de Nefrologia i Urologia (ICNU), Hospital Clinic (HC), Barcelona.  3: Laboratori Experimental de Nefrologia i Trasplantament (LENIT), IDIBAPS, Barcelona

P-18  **Diffuse extent of peritubular capillaritis in late antibody mediated rejection – association with transplant glomerulopathy and more severe chronic allograft damage**

N. Kozakowski¹, F. Eskandary², H. Herkner³, G. Bond², D. Dalos⁴, H. Regele¹, R. Oberbauer², G. Böhmig², Z. Kiki²

1: Department of Pathology.  2: Division of Nephrology and Dialysis, Department of Medicine III.  3: Department of Emergency Medicine.  4: Division of Cardiology, Department of Medicine II, Medical University of Vienna, Austria

P-19  **IGG subclass of plasma cell-rich infiltrates in the kidney allograft**

S. Hara, T. Itoh

Diagnostic Pathology, Kobe University Graduate School of Medicine, Kobe, Japan

P-20  **Prolonged prophylaxis with Valgancyclovir prevents CMV disease in CMV high risk kidney transplant recipients**

F. Halleck, D. Khadzhynov, K. Budde, O. Staeck

Nephrology, Charité Berlin, Germany

P-21  **The utility of Oxford classification for IGA nephropathy in renal allograft recipients**


Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS)

P-22  **Kidney allograft histology in patients with transplantation vintage longer than 20 years: tremendous effects of donor age**

T. Namba¹, M. Kyo², T. Hamano³, Y. Yamaguchi⁴, Y. Isaka¹, S. Takahara⁵

1: Nephrology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.  2: Sakurabashi Iseikai Clinic, Dialysis center.  3: Osaka University Graduate School of Medicine, Comprehensive Kidney Disease Research.  4: Yamaguchi’s Pathology Laboratory.  5: Osaka University Graduate School of Medicine, Advanced Technology for Transplantation
P-23  
**Donor-specific anti-HLA antibodies accelerate the progression of interstitial fibrosis in the kidney allograft**

C. Gosset¹, D. Viglietti², M. Rabant³, D. Glotz⁴, C. Legendre⁵, J.P. Duong Van-Huyen⁶, A. Loupy², C. Lefaucheur²

1: Pathology, Saint Louis Hospital. 2: Paris Translational Research Center for Organ Transplantation. 3: Pathology, Necker Hospital. 4: Nephrology and Kidney Transplantation, Saint Louis Hospital. 5: Nephrology and Kidney Transplantation, Necker Hospital, Paris, France

---

P-24  
**Long-term outcomes of kidney transplant recipients with primary idiopathic FSGS**

O. Staëck, F. Halleck, K. Budde, D. Khadzhynov

Nephrology, Charité Universitätsmedizin Berlin, Germany.

---

P-25  
**Brain-dead donors terminal inflammation is associated to delayed graft function in kidney transplant recipients**

D. Cucchiarì¹, F. Diekmann², P. Ventura-Aguir², J. Rovira², D. Paredes³, R. Adália³, F. Oppenheimer², I. Revuelta²

1: Renal Transplant Unit, Hospital Clínic, Barcelona. 2: Laboratori Experimental de Nefrologia i Trasplantament (LENIT), Fundació Clínic, IDIBAPS - Barcelona. 3: Transplant Coordination Unit, Hospital Clínic, Barcelona

---

P-26  
**Prolonged low-dose prophylaxis with valganciclovir in CMV D+/R- kidney transplant recipients allows seroconversion and prevents CMV disease**

F. Halleck, D. Khadzhynov, O. Rissling, K. Budde, O. Staëck

Nephrology, Charité Universitätsmedizin Berlin, Germany

---

P-27  
**The current Banff classification of BK polyomavirus-associated nephropathy does not accurately stratify patients at risk for progressive renal graft failure**

Y. Bouatou¹, J. Roelofs¹, F. Bemelman², J. Kers¹, S. Florquin¹

1: Pathology, 2: Nephrology, AMC, Amsterdam, Netherlands

---

P-29  
**Donor-recipient relationship significantly influences the long-term immunologic outcome in living related kidney transplantation**

D. Khadzhynov, F. Halleck, L. Lehner, D. Schmidt, K. Budde, O. Staëck

Nephrology, Charité Universitätsmedizin Berlin, Germany

---

P-30  
**Evaluation of frozen and paraffin sections using the MAPI-Score in kidneys donor’s biopsies of a Brazilian cohort**

A. Costa Teixeira¹, V. Sobreira Lacerda², C. Costa Freire De Carvalho³, G. Pinho Mororo², L. Dourado Mapurunga Pereira², R. Matos Esmeraldo⁴

1: Renal Pathology, Argos Pathology. 2: Faculty of Medicine, Unichristus. 3: Faculty of Medicine, University of Fortaleza. 4: Department of Transplantation, General Hospital of Fortaleza, Fortaleza, Brazil
**P-31**

**Acute transplant arteritis resulting in sudden death in cardiac transplant patients**

J. Dallan¹, S. Self², N. Batalis¹, O. Moussa¹, T. Hulsey³, A. Van Bake¹⁴, E. Bruner¹

1: Pathology, University of Kentucky, Lexington, KY, USA. 2: Pathology, 3: Pediatrics, 4: Medicine, Medical University of South Carolina, Charleston, SC, USA

**P-32**

**Thrombotic microangiopathy in renal allograft biopsies: minimal histopathological criteria and spectrum**

M. Afrouzian¹, J.U. Becker², S. Seshan³, H. Liapis⁴

1: Department of Pathology, University of Texas Medical Branch (UTMB), Galveston, USA. 2: Institute of Pathology, University Hospital of Cologne, Cologne, Germany. 3: Department of Pathology, Weill Cornell Medicine, New York, USA. 4: Department of Pathology, Washington University School of Medicine, St. Louis, USA

**P-33**

**Outcome assessment in kidney transplantation using different clinical pretransplant kidney donor variables: is KDPI useful?**

C. Arias-Cabral⁵, M.J. Pérès-Sáez¹, D. Redondo-Pachón¹, A. Buxeda¹, C. Burballa¹, S. Bermejo¹, A. Sierra¹, M. Mir¹, A. Buron², A. Zapatero³, M. Crespo¹, J. Pascual¹

1: Nefrología. 2: Epidemiology and Evaluation. 3: Intensive Care Medicine, Hospital del Mar, Barcelona

**P-35**

**The effects of MYD88 inhibitor local infusion in ischemia-reperfusion kidney injury**

H.J. Kim¹, H.J. Cha², J.S. Lee³, H.R. Cho⁴, B. Kwon¹

1: Biomedical Research Center, University of Ulsan, Ulsan, Korea (South). 2: Department of Pathology, University of Ulsan. 3: Department of Internal Medicine-Nephrology. 4: Department of Surgery-Transplantation, University of Ulsan, Ulsan, Korea

**P-36**

**An accurate method for cell quantification of the inflammatory infiltrates in plasma cell-rich rejection liver transplant biopsies**

E. Aguado-Dominguez¹, L. Gomez², J.M. Sousa³, M.A. Gomez-Bravo⁴, A. Nuñez-Roldan⁻¹, I. Aguilera¹

1: Immunology, Instituto de Biomedicina de Sevilla IBiS. 2: Pathology, Instituto de Biomedicina de Sevilla. 3: Digestive Diseases, 4: Liver Transplant Unit, H.U. Virgen del Rocio, Sevilla

**P-37**

**Renal allograft biopsy computerized inflammatory cell quantitation for rejection assessment: comparison of commercial and open source image analysis algorithms**

A. Moon, G. Smith, T. Rogers, C. Ellis, B. Farris

Department of Pathology, Emory University, Atlanta, United States
P-38 Oxalate deposition in the renal allograft biopsy within 3 months after transplantation

M.L.H. Snijders¹, J.I. Roodnat², D.A. Hesselink², M.C. Claesen-van Groningen¹
1: Department of Pathology, 2: Department of Nephrology and Transplantation, Erasmus MC, Rotterdam, The Netherlands
THURSDAY

18.30 Joint Poster Session 2

P-39 C reactive protein is modulated by subclinical inflammation in kidney allograft surveillance biopsies
C. García-Carro¹, C. Dörje², A. Åsberg², K. Midtvedt², H. Holdaas², A.V. Reisæter², D. Seron¹
1: Nephrology, Hospital Vall d’Hebron, Barcelona. 2: Trasplant Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway

P-40 Clinical and pathological analyses of acute vascular rejection cases after kidney transplantation
T.S. Shimizu¹, H.I. Hideki¹, K.U. Kohei¹, M.O. Masayoshi¹, K.T. Kazunari¹, K.H. Kazuho², J.K. Junki³
1: Department of Urology, Tokyo Women’s Medical University, Tokyo. 2: Department of Anatomy, Showa University, Tokyo. 3: Department of Pathology, Kawasaki Municipal Tama Hospital, Kanagawa, Japan

P-41 Aged donors can produce graftable limbal stem cells
N. Nieto-Nicolau¹, R.A. Martinez Gª de la Torre¹, R.P. Casaroli-Marano²
1: Cell Biology, 2: Department of Surgery & Hospital Clinic de Barcelona, University of Barcelona

P-42 Rejection phenotypes in the current era of immunosuppression
H. Hopfer¹, C. Wehmeier², P. Amico², P. Hirt-Minkowski², A. Georgalis², G. Hönger², T. Menter¹, M.J. Mihatsch¹, F. Burkhalter², J. Steiger², M. Dickenmann², S. Schaub²
1: Pathology, 2: Transplantation Immunology and Nephrology, University Hospital Basel, Basel, Switzerland

P-43 A comparison of ultrastructural glomerular features in biopsies from patients with de novo donor specific antibodies with surveillance biopsies
L. Moran¹, J. Moss¹, M. Willicome², E. Diyenli¹, L. Rasch³, P. Brookes⁴, J. Galliford², A. McLean², D. Taube², T. Cook⁵, C. Roufosse⁵
1: Electron Microscopy, 2: Renal Medicine, 3: Centre for Complement and Inflammation Research, Imperial College. 4: Tissue Typing, 5: Cellular Pathology, and Centre for Complement and Inflammation Research, Imperial College Healthcare NHS Trust, London, UK

P-44 Early loss of peritubular capillaries after kidney transplantation is associated with later renal function decline: a validation study in 121 patients
A.A. Keijbeck¹, F.M.E.G. Steegh¹, M.A.C.J. Gelens², E.L.W. van Heurn³, M.H.L. Christiaans², C.J. Peutz-Kootstra¹
1: Pathology, Maastricht University Medical Centre, Maastricht, Netherlands. 2: Internal Medicine, Maastricht University Medical Centre, Maastricht, Netherlands. 3: Surgery, Academic Medical Centre, Amsterdam, Netherlands
P-45 Retrospective analysis of kidney transplant recipients with antibody-mediated rejection
G. Piñeiro¹, E. De Sousa¹, J. Villarreal¹, M. Lozano², J. Cid², M. Solé³, M. Jimenez¹, F. Oppenheimer¹, F. Diekmann¹
1: Nephrology and Renal Transplant, 2: Apheresis Unit, Department of Hemothreapy and Hemostasis, 3: Pathology, Hospital Clinic de Barcelona

P-46 MDRD or CKD-EPI for the estimation of living kidney donor’s renal function
C. Burballa¹, M. Crespo¹, D. Redondo-Pachón¹, M.J. Pérez-Sáez¹, M. Mir¹, L. Fumadó³, A. Francés², J.M. Puig¹, L. Cecchini², J. Pascual¹
1: Department of Nephrology. 2: Department of Urology, Hospital del Mar, Barcelona

P-48 Determination of the culture time point to induce corneal epithelial differentiation in iPS C
R.A. Martínez¹, N. Nieto-Nicolau¹, A. Morales-Pastor¹, R.P. Casaroli-Marano²
1: Cell Biology, University of Barcelona. 2: Department of Surgery & Hospital Clínic de Barcelona, University of Barcelona

P-49 Adipose derived mesenchymal stem cells (ADS) bioengineered grafts for ocular surface regeneration
R.P. Casaroli-Marano¹, R.A. Martínez Gª de la Torre², N. Nieto-Nicolau²
1: Department of Surgery & Hospital Clinic de Barcelona, University of Barcelona. 2: Cell Biology, University of Barcelona

P-50 Ductular reaction and hepatocyte ballooning indentify patients with fibrosing cholestatic hepatitis (FCH) after liver transplantation
L. P. Llovet¹, S. Rodriguez-Tajes¹, M.C. Londoño¹, C. Montironi², S. Sciarrone³, C. Mescoli³, M. Rugge³, P. Burra³, X. Forn¹, A. Diaz², G. Crespo¹
1: Liver Transplant Unit, Hospital Clinic, IDIBAPS, CIBERehd, Barcelona. 2: Pathology Department, Hospital Clinic, Barcelona. 3: Padova University Hospital

P-51 Dual kidney transplantation in the same recipient: a systematic review
D. Redondo¹, N. Montero², M.J. Pérez-Sáez¹, M. Crespo¹, J. Pascual¹
1: Department of Nephrology, Hospital del Mar, Barcelona. 2: Department of Nephrology, Hospital de Bellvitge, Barcelona

P-52 Analising donation and transplantation of cardiovascular tissue
M.L. Pérez¹, E. Agusti¹, A. Vilarrodon¹, R.P. Casaroli-Marano², E. Trias¹
1: Barcelona Tissue Bank, Banc de Sang i Teixits, Barcelona. 2: Departamento de Cirugía Facultad de Medicina - Universidad de Barcelona
P-53  **Chronic infection by hepatitis C virus and the development of transplant glomerulopathy**
D. Regidor¹, M.A. Martínez², N. Polanco³, F. Díaz-Crespo⁴, F.J. Ahijado¹, R. Díaz-Tejeiro¹, M.A. Fernández¹, M. Romero¹, E. García¹, J.M. Morales⁵
1: Nephrology, Hospital Virgen de la Salud de Toledo. 2: Pathology, Hospital Doce de Octubre, Madrid. 3: Nephrology, Hospital Doce de Octubre, Madrid. 4: Pathology, Hospital Virgen de la Salud de Toledo. 5: Investigation Institute, Hospital Doce de Octubre, Madrid

P-54  **Intratubular calcification of renal allografts detected by protocol biopsies: a new classification. The purple study**
A. Coloma¹, N. Díaz-Novo¹, R. Fornos¹, M. Solé², J.V. Torregrosa¹
1: Renal Transplant Unit. 2: Pathology Department, Hospital Clínic, Barcelona

P-55  **Diagnostic value of peritubular capillary density in early renal allograft biopsies**
V. Agrawal, N. Prasad, V. Agarwal
Pathology, SGPGIMS, Lucknow, India

P-56  **Kidney graft evolution in hepatorenal transplant with immunological risk**
G. Piñeiro¹, A. Sanchez¹, J. Colmenero², M. Navasa², J. Martorell³, V. Torregrosa¹, N. Esforzado¹
1: Nephrology and Kidney Transplant, 2: Liver Transplantation Unit, 3: Immunology, Hospital Clínica de Barcelona, Barcelona

P-57  **Renal transplantation for patients with autosomal dominant polycystic kidney disease: long term follow-up and importance of intracranial aneurysms on outcomes**
Department of Nephrology, Hospital del Mar, Barcelona

P-59  **Modulation of leukocyte-endothelium interactions with RATGS after ischemia-reperfusion injury in an experimental human perfusion model**
A.B. Beiras-Fernandez¹, I.W. Werner², P.W. Wang², A.M. Moritz², C.F.V. Vahl¹
1: Cardiothoracic and Vascular Surgery, Universitätsmedizin Mainz, Mainz, Germany. 2: Department of Experimental Surgery, University of Frankfurt, Frankfurt, Germany

P-60  **Ectopic lymphoid structures are present in type I T-cell mediated kidney transplant rejection**
K. de Leur¹, M.C. Claesen-van Groningen², G.N. de Graaf¹, D.A. Hesselink¹, J.N. Samsom³, C.C. Baan³, K. Boer¹
1: Department of Internal Medicine, Transplantation Laboratory. 2: Department of Pathology. 3: Department of Pediatrics, Erasmus MC, Rotterdam, The Netherlands
P-61  
**Undetected lung cancer in candidates for lung transplantation with interstitial lung disease**

C. Berastegui Garcia¹, J. Sacanell², J. Riera², I. Sansano³, L. Romero⁴, I. Bello⁴, T. Pont⁵, C. Bravo Masgoret¹, V. Monforte¹, H. Sintes¹, M. Lopez¹, B. Saez¹, A. Roman¹

¹: Pulmonology, ²: intensive Care, ³: Pathology, ⁴: Thoracic Surgery, ⁵: Organ Procurement, Hospital Universitari Vall d’Hebron, Barcelona

P-62  
**Six-month surveillance biopsies with borderline changes are associated with worse allograft function irrespective of the severity of interstitial inflammation**

S. Kung¹, M. Tavakol², D. Dobi³, F. Vincenti¹, S. Chandran¹, Z. Laszik³

¹: Medicine/Nephrology, ²: Surgery, ³: Pathology, University of California San Francisco, San Francisco, United States

P-63  
**A study of the relationship between peritubular capillary basement membrane multilayering and time post transplantation**

L. Moran¹, J. Moss¹, L. Bellaramani², E. Diyenli², M. Willicombe², T. Cook⁴, C. Roufosse³

¹: EM Unit, Imperial College Healthcare NHS Trust. ²: Dept Complement and Inflammation Research, Imperial College. ³: Dept Renal Medicine, Imperial College Healthcare NHS Trust. ⁴: Cellular Pathology, Imperial College Healthcare NHS Trust, London, UK

P-65  
**Macrophage density in 6-week surveillance biopsies predicts future renal transplant function at 4 years post transplantation**

J.H. Bräsen¹, A. Khalifa¹, J. Schmitz¹, W. Dai¹, G. Einecke², A. Schwarz², M. Hallensleben³, B.M.W. Schmidt², H.H. Kreipe¹, H. Haller², S. von Vietinghoff²

¹: Nephropathology, Institute for Pathology. ²: Department of Internal Medicine, Division of Nephrology and Hypertension. ³: Institute for Transfusion Medicine, Hannover Medical School, Hannover, Germany

P-66  
**Factors affecting kidney allograft outcome in transplant glomerulopathy**

C. Cassol¹, J.R. Braga², J. Kim³, R. John¹

¹: Laboratory Medicine and Pathobiology, University of Toronto. ²: Institute for Health Policy, Management and Evaluation, Faculty of Medicine, University of Toronto. ³: Division of Nephrology and the Kidney Transplant Program, Department of Medicine, Toronto General Hospital, University Health Network, University of Toronto. Toronto, Canada
P-67  Donación en asistolia controlada (DAC) con canulación rápida en el Hospital Universitario Vall d’Hebron. Resultados de un año y medio de experiencia
C. Mazo Torre¹, A. Sandiumenge¹, F. Moreo², J. Morote³, R. Charco⁴, J. Sole⁵, T. Pont¹
1: Coordinación de Trasplante, Hospital Universitari Vall d’Hebron, Barcelona. 2: Servicio de Nefrología, 3: Servicio de Urología, 4: Servicio de Cirugía Hepática, 5: Servicio de Cirugía Torácica

P-68  High-speed mass spectrometry imaging identifies lipid degradation products in kidney donor tissue that are associated with severity of ischemic injury
T.C. van Smaalen¹, S.R. Ellis², N.E. Mascini², T. Porta², B. Cillero-Pastor², L.M. Hillen³, L.W.E. van Heurn⁴, C.J. Peutz-Kootstra³, R.M.A. Heeren²
1: Department of Surgery, Maastricht University Medical Center, Maastricht, Netherlands. 2: M4I, The Maastricht Multimodal Molecular Imaging Institute. 3: Department of Pathology, Maastricht University Medical Center. 4: Department of Surgery, Amsterdam Medical Center, Amsterdam, The Netherlands

P-69  Quantitative image analysis combined with tissue-based gene expression profiling has the potential to improve the diagnosis of Banff’s ‘borderline changes’ category
D. Dobi¹, S. Bowman¹, S. Chandran², F. Vincenti², Q. Tang³, Z. Laszik¹
1: Department of Pathology, University of California, San Francisco, USA. 2: Department of Medicine, Division of Nephrology, University of California, San Francisco, USA. 3: Department of Surgery, Division of Transplant Surgery, Transplantation Research Laboratory, University of California, San Francisco, USA

P-70  Size matters: kidney biopsy sample size has major impact on the diagnosis of Banff’s ‘borderline changes’ in cases with low inflammatory load
D. Dobi¹, F. Vincenti², S. Chandran², Z. Laszik¹
1: Department of Pathology, University of California, San Francisco, USA. 2: Department of Medicine, Division of Nephrology, University of California, San Francisco, USA
Assessment of cytomegalovirus (CMV) specific immune response measured by quantiferon and overall immune response measured by Immuknow® in lung transplant patients with positive CMV serology pre-transplantation

H. Sintes¹, V. Monforte¹, P. Ussetti², V. Pérez³, F. Santos⁴, A. Solé⁵, J.M. Borro⁶, J. Cifrián⁷
1: Pulmonology, Hospital Universitario Vall d’Hebron, Barcelona.
2: Pulmonology, Hospital Universitario Puerta de Hierro, Madrid.
3: Pulmonology, Hospital Universitario Doce de Octubre, Madrid.
4: Pulmonology, Hospital Universitario Reina Sofía, Córdoba.
5: Pulmonology, Hospital Universitario La Fe, Valencia.
6: Pulmonology, Hospital Universitario A Coruña.
7: Pulmonology, Hospital Universitario Marques de Valdecilla, Santander

Panel reactive antibodies is a debatable indicator of post-transplant function and survival

M.L. McCahery¹, A.T. Rowshani², K.A.L. Mauff³, J.A. Kal- van Gestel², M.C. Clahsen- van Groningen¹
1: Department of Pathology,
2: Department of Nephrology & Transplantation,
3: Department of Biostatistics, Erasmus Medical Centre Rotterdam,
Rotterdam, The Netherlands

Enteric drainage of pancreas transplantation. Clinical impact of intra-abdominal complications

J. Ferrer¹, B. Cano-Vargas², L. Martinez De La Maza¹, Ma López-Boado¹, R. Rull¹, Mj Ricart³, P. Ventura³, E. Enric⁴, S. Sánchez¹, J. Fuster¹, Jc García-Valdecasas¹
1: Hepato-bilio-pancreatic Surgery and Transplantation Department, Hospital Clinic, Barcelona.
2: Hospital General Centro Médico Nacional La Raza, México.
3: Renal Transplant Unit, Hospital Clinic, Barcelona.
4: Diabetes Unit, Hospital Clinic, Barcelona

Experimental porcine model in pancreas transplantation

J. Ferrer¹, V. Molina¹, Jn Hidalgo¹, R. Pujo³, L. Gómez², P. De La Calle³, Ma López-Boado¹, J. Fuster¹, L. Fernández-Cruz¹, Jc García-Valdecasas¹
1: Hepato-bilio-pancreatic Surgery and Transplantation Department, Hospital Clinic, Barcelona.
2: Department of Anesthesiology, Hospital Clinic, Barcelona.
3: Universidad de Alcalá de Henares, Madrid
P-77  Glomerulocapillary miRNA signatures in three models of antibody-mediated rejection  
G. Dieplinger², V. Grau³, F.M. Heinemann⁴, P.T. Jindra⁵, U. Eisenberger⁶, J.U. Becker⁷  
1: Institute of Pathology, University Hospital of Cologne, Cologne, Germany.  
2: Department of General, Visceral and Cancer Surgery, Transplant Center Cologne, University of Cologne, Cologne, Germany.  
3: Laboratory of Experimental Surgery, Department of General and Thoracic Surgery, Justus-Liebig-University Giessen, Giessen, Germany.  
4: Institute for Transfusion Medicine, University Hospital Essen, University Duisburg-Essen, Essen, Germany.  
5: Immune Evaluation Laboratory, Department of Surgery, Baylor College of Medicine, Houston, TX, USA.  
6: Clinic for Nephrology, University Hospital Essen, University Duisburg-Essen, Germany  

P-78  Prevalence of histopathological abnormalities detected at time pre-implantation renal biopsy among living kidney donors  
M. Abdelrahim, D. Dahab  
Urology and Nephrology Center, Mansoura University, Egypt
Industry sponsored symposia
# INDUSTRY SPONSORED SYMPOSIA

## MONDAY 27 MARCH

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
<th>Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.00 - 15.00</td>
<td><strong>Symposium 1 by Thermo Fisher</strong> · Symposium Paranimf Room</td>
<td>Symposium Paranimf Room</td>
<td>Lynn Cornell, USA; Alexandre Loupy, France</td>
</tr>
<tr>
<td>14.00 - 14.30</td>
<td><strong>10 years development of antibody characterization assays: progress, clinical relevance and unmet needs</strong></td>
<td></td>
<td>Dr. Carmen LeFaucher, Paris, France</td>
</tr>
<tr>
<td>14.30 - 15.00</td>
<td><strong>The path toward next generation sequencing application to solid organ transplants</strong></td>
<td></td>
<td>Prof. Peter Nickerson, Manitoba, USA</td>
</tr>
</tbody>
</table>

## TUESDAY 28 MARCH

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
<th>Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.00 - 15.00</td>
<td><strong>Symposium 2 by Shire</strong> · Symposium Paranimf Room</td>
<td>Symposium Paranimf Room</td>
<td>Dr. Joana Sellares, Spain; Anat Tambur, USA</td>
</tr>
<tr>
<td>14.05 - 14.25</td>
<td><strong>Pathomechanisms of ABMR</strong></td>
<td></td>
<td>Rob Fairchild, Ph.D., Cleveland, USA</td>
</tr>
<tr>
<td>14.25 - 14.45</td>
<td><strong>New drugable targets in ABMR</strong></td>
<td></td>
<td>Prof. Steve Woodle, Cincinnati, USA</td>
</tr>
<tr>
<td>14.45 - 14.55</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## WEDNESDAY 29 MARCH

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
<th>Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>13.00 - 14.00</td>
<td><strong>Symposium 3 by Astellas</strong> · Symposium Aula Magna Room</td>
<td>Symposium Aula Magna Room</td>
<td>Dr. Daniel Serón, Spain</td>
</tr>
<tr>
<td></td>
<td><strong>Tacrolimus minimization impact on graft outcomes, new insights</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Tacrolimus minimization and histological lesions</strong></td>
<td></td>
<td>Dr. Daniel Serón, Barcelona, Spain</td>
</tr>
<tr>
<td></td>
<td><strong>Minimisation, variability and clinical management</strong></td>
<td></td>
<td>Dr. Lluís Guirado, Barcelona, Spain</td>
</tr>
<tr>
<td></td>
<td><strong>Liver alloimmunity: still so different from kidney?</strong></td>
<td></td>
<td>Dra. María Londoño, Barcelona, Spain</td>
</tr>
</tbody>
</table>

## THURSDAY 30 MARCH

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
<th>Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>13.00 - 14.00</td>
<td><strong>Symposium 4 by Chiesi</strong> · Symposium Paranimf Room</td>
<td>Symposium Paranimf Room</td>
<td>Dr. Pascual, Spain; Dr. Lauzurica, Spain</td>
</tr>
<tr>
<td></td>
<td><strong>Tacrolimus, ¿Puede ofrecernos mas?</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Diving into the Registry, what kind of patients do we transplant?</strong></td>
<td></td>
<td>Dr. Cruzado, Barcelona, Spain</td>
</tr>
<tr>
<td></td>
<td><strong>The challenge of individualisation: do we stay on the surface?</strong></td>
<td></td>
<td>Dr. Moreso, Barcelona, Spain</td>
</tr>
<tr>
<td></td>
<td><strong>Envarsus, can we go deeper?</strong></td>
<td></td>
<td>Dr. Gutiérrez, Zaragoza, Spain</td>
</tr>
<tr>
<td></td>
<td><strong>Discussion</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
2017 BANFF-SCT
Joint Scientific Meeting

Index of speakers
Afrouzian, Marjan
Banff Working Groups: Up-dates from Banff Working Groups
Tuesday 28 March, 11.00 - 13.00

Akalin, Enver
Banff Concurrent: Kidney 1. The significance of i-IFTA: revisiting TCMR and mixed rejection
Tuesday 28 March, 15.00 - 19.00

Alachkar, Nada
Banff Working Groups: Up-dates from Banff Working Groups
Tuesday 28 March, 11.00 - 13.00

Angelini, Annalisa
Banff Concurrent: Heart
Tuesday 28 March, 15.00 - 18.30

Bagnasco, Serena
Banff Working Groups: Up-dates from Banff Working Groups
Tuesday 28 March, 9.00 - 10.30

Bartlett, Stephen
Banff Concurrent: Pancreas
Wednesday 29 March, 15.00 - 18.30

Becker, Jan Ulrich
Banff Concurrent: Kidney 2
Thursday 30 March, 15.00 - 19.00

Bello, Irene
SCT Plenary 5. The future of DCD in solid organ transplantation
Friday 31 March, 9.00 - 11.00

Berry, Gerald
Banff Concurrent: Lung. Antibody-mediated rejection, to be continued!
Tuesday 28 March, 15.00 - 19.00
Banff Concurrent: Heart
Wednesday 29 March, 15.00 - 18.30

Bestard, Oriol
SCT Plenary 4. Precision medicine in solid organ transplantation
Thursday 30 March, 15.00 - 17.30

Branchezau, Julien
Banff Concurrent: Pancreas
Wednesday 29 March, 15.00 - 18.30

Brunet, Mercè
SCT Plenary 4. Precision medicine in solid organ transplantation
Thursday 30 March, 15.00 - 17.30

Bruneval, Patrick
Banff Concurrent: Heart
Wednesday 29 March, 15.00 - 18.30
Banff Summary and Closing Remarks
Friday 31 March, 9.00 - 11.00

Calabrese, Fiorella
Banff Concurrent: Lung. Antibody-mediated rejection, to be continued!
Tuesday 28 March, 15.00 - 19.00

Cantarovich, Diego
Banff Concurrent: Pancreas
Wednesday 29 March, 15.00 - 18.30

Caralt, Mireia
SCT Plenary 1. State of the art: cellular repair of damaged organs
Wednesday 29 March, 10.30 - 11.30

Cendales, Linda
Banff Plenary 2. Staging and grading of rejection: the need in the era of precision medicine
Thursday 30 March, 11.00 - 12.00
Banff Summary and Closing Remarks
Friday 31 March, 11.30 - 13.00

Ciria, Rubén
SCT Plenary 5. The future of DCD in solid organ Transplantation
Friday 31 March, 9.00 - 11.00

Coll, Elisabeth
SCT Plenary 3. How to increase the donor pool
Thursday 30 March, 9.00 - 10.30
SCT Plenary 5. The future of DCD in solid organ Transplantation
Friday 31 March, 9.00 - 11.00
INDEX OF SPEAKERS

Colvin, Robert  
Banff Pre-Meeting: New end-points for next generation clinical trials  
Monday 27 March, 09.00-10.45  
Banff Symposium: The molecular microscope in routine transplantation pathology  
Thursday 30 March, 08:00 – 9.00

Cornell, Lynn  
Banff Concurrent: Kidney 1. The significance of i-IFTA: revisiting TCMR and mixed rejection  
Tuesday 28 March, 15.00 - 19.00

Demetreis, Anthony Jake  
Banff Concurrent: Liver 1  
Tuesday 28 March, 15.00 - 19.00  
Banff Summary and Closing Remarks  
Friday 31 March, 09.00 - 11.00

DiBernardo, Louis  
Banff concurrent: VCA  
Vascular changes in a transplanted organ  
Wednesday 29 March, 15.00 – 18.30

Drachenberg, Cinthia  
Banff Summary and Closing Remarks  
Friday 31 March, 09.00 - 11.00

Duong Van Huyen, Jean-Paul  
Banff Plenary 2. Staging and grading of rejection: the need in the era of precision medicine  
Thursday 30 March, 11.00 - 12.00

Elder, David  
Banff Concurrent: VCA  
Wednesday 29 March, 15.00 - 18.30

Fairchild, Rob  
Symposium 2. The natural history of ABMR: the known, the unknown, and the known unknown  
Tuesday 28 March, 14:00 – 15.00

Fedrigo, Marny  
Banff Concurrent: Heart  
Wednesday 29 March, 15.00 – 18.30

Feng, Sandy  
Banff Pre-Meeting: New end-points for next generation clinical trials  
Monday 27 March, 09.00-10.45  
Banff Concurrent: Liver 2  
Thursday 30 March, 15.00 - 19.00

Fishbein, Gregory A.  
Banff Concurrent: Heart  
Wednesday 29 March, 15.00 - 18.30

Fondevila, Constantino  
SCT Plenary 5. The future of DCD in solid organ Transplantation  
Friday 31 March, 09.00 – 11.00

Gibson, Ian  
Banff Concurrent: Kidney 1. The significance of i-IFTA: revisiting TCMR and mixed rejection  
Tuesday 28 March, 15.00 - 19.00

Gosset, Clement  
Banff Concurrent: Kidney 1. The significance of i-IFTA: revisiting TCMR and mixed rejection  
Tuesday 28 March, 15.00 - 19.00

Gouw, Annette  
Banff Concurrent: Liver 1  
Tuesday 28 March, 15.00 - 19.00

Grinyó, Josep Maria  
SCT Plenary 2. Key issues in clinical trials in solid organ transplantation  
Wednesday 29 March, 15.00 – 16.30

Haas, Mark  
Banff Plenary 1. The integrated Diagnosis: Histology + DSA  
Wednesday 29 March, 08.30 – 10.00  
Banff Plenary 2. Starting and granding of rejection: the need in the era of precision medicine  
Thursday 30 March, 11.00 - 12.00  
Banff Summary and Closing Remarks  
Friday 31 March, 09.00 – 11.00

Hachem, Ramsey  
Banff Concurrent: Lung. Antibody-mediated rejection, to be continued!  
Tuesday 28 March, 15.00 - 19.00
Halloran, Philip
Banff Pre-Meeting: New end-points for next generation clinical trials
Monday 27 March, 11.15 - 13.00
Banff Concurrent: Lung. Antibody-mediated rejection, to be continued!
Tuesday 28 March, 15.00 - 19.00
Banff Symposium: The molecular microscope in routine transplantation pathology
Thursday 30 March, 8:00 - 9.00

Hernández, Maria
SCT Plenary: 4. Precision medicine in solid organ transplantation
Thursday 30 March, 15.00 - 17.30

Hesselink, Dennis
SCT Plenary 4. Precision medicine in solid organ transplantation
Thursday 30 March, 15.00 - 17.30

Hübscher, Stefan
Banff Concurrent: Liver 1
Tuesday 28 March, 15.00 - 19.00

Huibers, Manon
Banff Concurrent: Heart
Wednesday 29 March, 15.00 - 18.30

Hwang, David
Banff Summary and Closing Remarks
Friday 31 March, 11.30 - 13.00

Junge, Guido
SCT Plenary 2. Key issues in clinical trials in solid organ transplantation
Wednesday 29 March, 15.00 - 16.30

Kanitakis, Jean
Banff Concurrent: VCA
Wednesday 29 March, 15.00 - 18.30

Krush, Kiran
Banff Concurrent: Heart
Wednesday 29 March, 15.00 - 18.30

Large, Stephen
SCT Plenary 5. The future of DCD in solid organ Transplantation
Friday 31 March, 9.00 - 11.00

LeFaucher, Carmen
Symposium 1
Monday 27 March, 14:00 - 15.00
Banff Plenary 1. The integrated Diagnosis: Histology + DSA
Wednesday 29 March, 8.30 - 10.00

Leone, Ornella
Banff Concurrent: Heart
Wednesday 29 March, 15.00 - 18.30

Levine, Deborah
Banff Concurrent: Lung. Antibody-mediated rejection, to be continued!
Tuesday 28 March, 15.00 - 19.00

Loupy, Alexandre
Banff Pre-Meeting: New end-points for next generation clinical trials
Monday 27 March, 15.00 - 17.30

Mannon, Roz
Banff Concurrent: Kidney 1. The significance of i-IFTA: revisiting TCMR and mixed rejection
Tuesday 28 March, 15.00 - 19.00

Mengel, Michael
Banff Working Groups: Up-dates from Banff Working Groups
Tuesday 28 March, 09.00-10.30
Banff Working Groups: Up-dates from Banff Working Groups
Tuesday 28 March, 11.00 - 13.00
Banff Concurrent: Heart
Wednesday 29 March, 15.00 - 18.30

Miller, Dylan
Banff Concurrent: Heart
Wednesday 29 March, 15.00 - 18.30

Molne, Carl Johan
Banff Concurrent: VCA
Wednesday 29 March, 15.00 - 18.30

Moreso, Francesc
SCT Plenary 3. How to increase the donor pool
Thursday 30 March, 9.00 - 10.30
<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
<th>Date and Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Naessen, Maarten</td>
<td>Banff Concurrent: Kidney 1. The significance of i-IFTA: revisiting TCMR and mixed rejection</td>
<td>Tuesday 28 March, 15.00 – 19.00</td>
</tr>
<tr>
<td>Nankivell, Brian</td>
<td>Banff Concurrent: Kidney 1. The significance of i-IFTA: revisiting TCMR and mixed rejection</td>
<td>Tuesday 28 March, 15.00 – 19.00</td>
</tr>
<tr>
<td>Navasa, Miquel</td>
<td>SCT Plenary 5. Precision medicine in solid organ transplantation</td>
<td>Thursday 30 March, 15.00 – 17.30</td>
</tr>
<tr>
<td>Nickeleit, Volker</td>
<td>Banff Working Groups: Up-dates from Banff Working Groups</td>
<td>Tuesday 28 March, 11.00 – 13.00</td>
</tr>
<tr>
<td></td>
<td>Banff Concurrent: Kidney 2</td>
<td>Thursday 30 March, 15.00 – 19.00</td>
</tr>
<tr>
<td>Nickerson, Peter</td>
<td>Symposium 1</td>
<td>Monday 27 March, 14:00 – 15.00</td>
</tr>
<tr>
<td></td>
<td>Banff Plenary 1. The integrated diagnosis: histology + DSA</td>
<td>Wednesday 29 March, 8.30 – 10.00</td>
</tr>
<tr>
<td>Oberbauer, Rainer</td>
<td>SCT Plenary 3. How to increase the donor pool</td>
<td>Thursday 30 March, 9.00 - 10.30</td>
</tr>
<tr>
<td>Papadimitriou, John</td>
<td>Banff Concurrent: Pancreas</td>
<td>Wednesday 29 March, 15.00 – 18.30</td>
</tr>
<tr>
<td>Pascual, Julio</td>
<td>SCT Plenary 2. Key issues in clinical trials in solid organ transplantation</td>
<td>Wednesday 29 March, 15.00 – 16.30</td>
</tr>
<tr>
<td>Porte, Robert</td>
<td>Banff Concurrent: Liver 1</td>
<td>Tuesday 28 March, 15.00 – 19.00</td>
</tr>
<tr>
<td>Portolés, José Maria</td>
<td>SCT Plenary 5. The future of DCD in solid organ Transplantation</td>
<td>Friday 31 March, 9.00 – 11.00</td>
</tr>
<tr>
<td>Potena, Luciano</td>
<td>Banff Pre-Meeting: New end-points for next generation clinical trials</td>
<td>Monday 27 March, 11.15 – 13.00</td>
</tr>
<tr>
<td>Randhawa, Parmjeet</td>
<td>Banff Working Groups: Up-dates from Banff Working Groups</td>
<td>Tuesday 28 March, 11.00 – 13.00</td>
</tr>
<tr>
<td></td>
<td>Banff Concurrent: Kidney 2</td>
<td>Thursday 30 March, 15.00 – 19.00</td>
</tr>
<tr>
<td>Revello, Patricia</td>
<td>Banff Concurrent: Heart</td>
<td>Wednesday 29 March, 15.00 – 18.30</td>
</tr>
<tr>
<td>Rosales, Ivy</td>
<td>Banff Concurrent: VCA VCA skin scoring system in a preclinical model</td>
<td>Wednesday 29 March, 15.00 – 18.30</td>
</tr>
<tr>
<td>Roufossé, Candice</td>
<td>Banff Concurrent: Kidney 2</td>
<td>Thursday 30 March, 15.00 – 19.00</td>
</tr>
<tr>
<td>Roux, Antoine</td>
<td>Banff Concurrent: Lung. Antibody-mediated rejection, to be continued!</td>
<td>Tuesday 28 March, 15.00 – 19.00</td>
</tr>
<tr>
<td>Sánchez-Fueyo, Alberto</td>
<td>Banff Concurrent: Liver 2</td>
<td>Thursday 30 March, 15.00 – 19.00</td>
</tr>
<tr>
<td>Schinstock, Carrie</td>
<td>Banff Working Groups: Up-dates from Banff Working Groups</td>
<td>Tuesday 28 March, 09.00-10.30</td>
</tr>
</tbody>
</table>
Segev, Dorry
Banff Pre-Meeting: New end-points for next generation clinical trials
Monday 27 March, 15.00 - 17.30

Serón, Daniel
SCT Plenary 2. Key issues in clinical trials in solid organ transplantation
Wednesday 29 March, 15.00 - 16.30

Serrano Mollar, Anna
SCT Plenary 1. State of the art: cellular repair of damaged organs
Wednesday 29 March, 10.30 - 11.30

Singh, Harsharan k.
Banff Working Groups: Up-dates from Banff Working Groups
Tuesday 28 March, 09.00-10.30
Banff Concurrent: Kidney 2
Thursday 30 March, 15.00 - 19.00

Solez, Kim
Banff Pre-Meeting: New end-points for next generation clinical trials
Monday 27 March, 9.00 - 10.45
Banff Summary and closing remarks
Friday 31 March, 11.30 - 13.00

Stegall, Mark
Banff Pre-Meeting: New end-points for next generation clinical trials
Monday 27 March, 11.15 - 13.00
Banff Pre-Meeting: New end-points for next generation clinical trials
Monday 27 March, 15.00 - 17.30

Tambur, Anat
Banff Pre-Meeting New end-points for next generation clinical trials
Monday 27 March,09.00 - 10.45

Taubert, Richard
Banff Concurrent: Liver 2
Thursday 30 March, 15.00 - 19.00

Toniolo, Maria Fernanda
Banff Concurrent: Pancreas
Wednesday 29 March, 15.00 - 18.30

Triñanes Ramos, Javier
Banff Concurrent: Pancreas
Wednesday 29 March, 15.00 - 18.30

Uva, Pablo
Banff Concurrent: Pancreas
Wednesday 29 March, 15.00 - 18.30

Venturi, Carla
Banff Concurrent: Liver 1
Tuesday 28 March, 15.00 - 19.00

Weissenbacher, Annemarie
Banff Concurrent: VCA
Wednesday 29 March, 15.00 - 18.30

White, Steven
Banff Concurrent: Pancreas
Wednesday 29 March, 15.00 - 18.30

Woodle, Steve
Symposium 2. The natural history of ABMR: the known, the unknown, and the known unknown
Tuesday 28 March, 14:00 - 15.00

Zeevi, Adriana
Banff Concurrent: Lung. Antibody-mediated rejection, to be continued!
Tuesday 28 March, 15.00 - 19.00
Banff Plenary 1. The integrated diagnosis: histology + DSA
Wednesday 29 March, 8.30 - 10.00
Main entrance to the University

Meeting venue: Universitat de Barcelona, Plaça Universitat, Gran Via de les Corts Catalanes 585, 08007 Barcelona
2017 BANFF-SCT
Joint Scientific Meeting

BARCELONA
29th March

SYMPOSIUM
ASTELLAS

TACROLIMUS MINIMIZATION IMPACT ON GRAFT OUTCOMES: NEW INSIGHTS
Redefiniendo el tratamiento con tacrolimus